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Abstract 
Introduction:  Ovarian cancer is a diverse disease with a poor survival rate and complex 
treatments that have potential significant morbidity.  The role of angiogenesis in ovarian 
cancer progression is well recognised and research into angiogenic inhibitors is novel and 
exciting.  Skin capillary density (SCD) is a dynamic marker that may provide a surrogate 
indicator of angiogenic activity and alter in response to treatment in cancer patients. 
Methods:  I conducted a longitudinal prospective cohort study to investigate skin capillary 
density in ovarian cancer.  I recruited 50 women with high grade serous carcinoma and 
measured SCD and angiogenic markers at five time points during treatment.  Longitudinal and 
survival analysis was conducted to ascertain changes in the variables during treatment and 
association with cancer outcomes including surgical resection, overall survival (OS) and 
progression free survival (PFS). 
Results:  Capillary rarefaction occurred in all patients during cytotoxic treatment.  Rarefaction 
also occurred in the subgroup who received anti angiogenic inhibitors and was correlated 
with a rise in blood pressure.  Baseline SCD was strongly associated with the outcome of 
debulking surgery. 
Conclusion:  In this thesis I have demonstrated a dynamic change in SCD during cytotoxic and 
anti angiogenic treatment in women with ovarian cancer.  Although this data requires 
validation in larger studies, it can be postulated that SCD could be useful as a biomarker of 
response to treatment and cancer outcomes and act as a surrogate marker of angiogenesis in 
cancer. It is a reproducible, cheap and non-invasive investigation that is acceptable to patients 
and shows promise in helping to guide treatment and prognostic information in the era of 
personalised medicine.  
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Chapter 1.  Introduction 
 
1.1.  Ovarian cancer 
 
1.1.1. Epidemiology 
Ovarian cancer is the most common gynaecological malignancy in developed countries.  There 
were over 7,000 new cases of ovarian cancer in the UK in 2014 and the incidence is projected 
to rise by 15% between 2014-2035.1  Ovarian cancer is associated with increasing age peaking 
in those aged 75-79 and over 53% of cases are diagnosed in women over 65 years.1 
Most ovarian cancers are diagnosed at a late stage with 55-58% diagnosed at stage III-IV.2, 3  
A strong prognostic factor for survival is the stage of disease at presentation.  Advanced stage 
ovarian cancer has a 5-year survival rate of 30-40%, while early stages have a 5-year survival 
of over 80%.4 
 
1.1.2.  Histopathology 
Ovarian cancer is a diverse disease and epidemiology, risk factors, pattern of spread, response 
to treatment and prognosis vary significantly according histological subtype.5 Consequently, 
as well as stage of disease histological subtype is fundamental to diagnosis and treatment 
when staging the disease.  The primary site of disease is also given at histological diagnosis as 
recommended by the International Federation of Gynaecology and Obstetrics (FIGO).6  
Ovarian cancers can be divided into five categories: epithelial, germ cell, sex cord stromal, 
metastatic and miscellaneous depending on their origin.  The most common type of ovarian 
malignancies are epithelial in origin (carcinomas) accounting for 80-90%.7 Five main 
 2 
histological subtypes of epithelial ovarian carcinoma include high-grade serous carcinoma 
(HGSC, 70%); endometrioid carcinoma (EC,10%); clear-cell carcinoma (CCC,10%); mucinous 
carcinoma (MC, 3%); and low-grade serous carcinoma (LGSC, <5%).6, 8  HGSC is the most 
common type.6   
The different histological subtypes of ovarian cancer are associated with distinctive molecular 
features and HGSC cancers often have inactivation of p53 (a tumour suppressor gene) and 
are associated with BRCA (Breast cancer Gene) mutations9.  BRCA genes are tumour 
suppressor genes that are important in cell DNA repair. 
The most common presentation for HGSCs is stage III where disease has spread along the 
peritoneal surfaces to involve both pelvic and abdominal peritoneum and omentum.6, 10  



























1.1.3.  Risk factors  
 
1.1.3.1. Genetic factors 
Up to a fifth of ovarian malignancies are associated with inherited conditions, the majority 
being linked with BRCA 1 and 2 mutations.12, 13  Both BRCA genes encode tumour suppressor 
proteins which are involved in DNA repair.  BRCA 1 and 2 mutations carry a significant 
increased risk of developing ovarian, breast, colon, pancreatic and prostate cancer.  In fact 
patients who have germline mutations in BRCA 1 and 2 have a higher risk of ovarian cancer 
compared to the general population with a cumulative risk by age 70 of 40-60%14 and 10-30% 
% respectively.15, 16  Women with Lynch syndrome have a 7% risk of developing ovarian cancer 
by 70 years17 and 21% of women with Peutz-Jeghers syndrome are at risk of developing the 
disease by 65.18  As well as mutations in BRCA 1 and BRCA 2, derangements in other genes 
BRIP1, PALB2, RAD51C, RAD51D AND BARD1 were found to make up 20% of mutations in a 
group of nearly 2000 patients with ovarian cancer.19 
 
Prophylactic risk reducing surgery is beneficial in prevention of ovarian cancer in women with 
germline BRCA mutation and bilateral salpingo-oophorectomy confers a 96% reduction in 
BRCA related ovarian cancer.19  Data in unselected populations suggests that salpingectomy 
reduces the risk of ovarian cancer by 35-50% and supports the concept that many high grade 
serous cancers begin in the fallopian tube.20  A study looking at PReventing Ovarian cancer 
Through early ExCision of Tubes and late Ovarian Removal (PROTECTOR) is ongoing to 
ascertain whether risk reducing salpingectomy only in pre menopausal women is effective in 
cancer prevention whilst avoiding morbidity from early surgical menopause.21 
 
 5 
Nonetheless patients with germline BRCA mutation have a survival benefit compared to those 
without.  This is likely to be multi factorial but increased sensitivity of platinum 
chemotherapy22 and the advent of new drug therapies such as PARP inhibitors are likely to 
be contributory to improved outcomes. 
 
1.1.3.2.Lifestyle factors 
Protective factors for ovarian cancer include reduction in the number of ovulations, thus 
increased parity, breastfeeding and use of oral contraceptive pills.23-25  Additionally these 
prove to be effective in reducing risk in those with inherited genetic mutations.26   Smoking 
and obesity particularly in premenopausal women increases the risk of ovarian cancer.27, 28 
 
1.1.3.3.Other factors 
It is now recognised that the distal fallopian tube is the likely origin of high grade serous 
disease and Yoon et al demonstrated a significant decrease in the risk of ovarian cancer in 
patients who underwent bilateral salpingectomy compared to controls (OR 0.51, 95% CI 0.35-
0.75).29 
 
1.1.4.Presentation and screening 
 
 
Symptoms of ovarian cancer are often vague and can be attributed to many other more 
common conditions.  Goff et al demonstrated that symptoms that were significantly 
associated with ovarian cancer were pelvic/abdominal pain, urinary urgency/frequency, 
increased abdominal size/bloating, and difficulty eating/feeling full when they were present 
for <1 year and occurred >12 days per month.30 
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The National Institute of Clinical Excellence (NICE) recommends that women over the age of 
50 should be offered a cancer antigen 125 (CA125) test if any of these symptoms are present 
persistently (>1 month) and frequently (>12 times a month).31 CA125 is a glycoprotein that is 
expressed on the epithelial surfaces of the female genital tract and is a recognised biomarker 
of ovarian cancer.  However, it should be recognised that only 50% of stage 1A cancers have 
a raised CA125 so the test does not achieve high specificity.32 
 
The UKCTOCS trial demonstrated a reduction in mortality over 7 years in those women who 
had serum Ca125 measurements or ultrasound to detect early cancer although this was not 
significant.33  With the lack of a reliable screening tool and the biological indolent nature of 





Primary debulking surgery followed by 6 cycles of platinum and taxane chemotherapy is the 
treatment of choice for ovarian cancer.34  An anti angiogenic therapy Bevacizumab has been 
demonstrated to have survival benefit when given to those patients with advanced disease 
or suboptimal surgical outcomes and is available via the cancer drug fund and is administered 
alongside chemotherapy after surgery.35  More recently poly ADP ribose polymerase (PARP) 




 Optimal surgery aims to achieve complete resection of disease, thus removing all visible 
disease or only leaving macroscopic disease <1cm in size.38  In the primary instance this may 
involve hysterectomy, bilateral salpingo-oophorectomy, appendicectomy, omentectomy and 
in many cases bowel resection, diaphragmatic stripping, splenectomy and peritoneal 
resection.  Primary surgery has a reported 30 day morbidity ranging from 11-67%.39  In those 
patients undergoing upper abdominal surgery to resect disease morbidity is likely to be higher 
due to the length and complexity of surgery.  Overall post-operative mortality has been 
reported as high as 2.8% although in more elderly patients this ranges between 5.4-11.7%.39   
Gerestien et al have developed a nomogram for predictive 30- day morbidity which includes 
age, WHO performance status (classification of physical activity), operative time and extent 
of surgery.40 
In many women the morbidity of surgery due to the advanced nature of the disease may 
mean that neoadjuvant chemotherapy is offered to reduce tumour bulk.  In this instance 
surgery is done as an interval procedure and followed by completion chemotherapy.  There 
has been much debate as to the benefits of primary cytoreduction with likely increased 
surgical morbidity vs interval debulking surgery.  However residual tumour after surgery and 
chemosensitivity are independent prognostic factors of recurrence and survival.41, 42  Results 
of the EORTC trial revealed no significant overall survival advantage for those women with 
stage IIIc and IV disease undergoing primary surgery vs neoadjuvant chemotherapy.  In fact 
post-operative morbidity and mortality was less after interval debulking surgery.42 
 
Nonetheless it appears that complete cytoreduction at surgery is the most important 
prognostic factor for survival.34, 43-47  The Gynaecological Oncologic Group (GOG) trials 
demonstrated that those patients with no residual disease had improved overall survival (OS) 
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compared to those with <1cm residual disease (64 months vs 29 months).44  This trial did note 
however that advanced disease at presentation remained a significant prognostic indicator 
even after complete cytoreduction was achieved surgically.44 
 
A Cochrane review which analysed 11 studies concluded that all attempts should be made by 
the surgeon to achieve complete cytoreduction at surgery.48  A meta analysis of six studies 
(3447 participants) found that women who were optimally debulked had more than twice the 
risk of death compared to those who had no macroscopic disease remaining (HR 2.20 95% CI 
1.90-2.54).  Furthermore, a meta-analysis of 2 studies of 464 participants demonstrated 
increased risk of death in those who were sub-optimally debulked (disease >1cm remaining) 
compared to those optimally debulked (<1cm remaining) (HR 1.36 CI 1.10-1.68).48  It is thus 
widely accepted that where complete cytoreduction is not achievable, any disease remaining 
should be small.  If suboptimal surgery is likely, women may not undergo attempt of 
cytoreduction at all due to the associated morbidity with no improvement in survival.  The 
data on surgical outcome is all retrospective and therefore likely to be associated with bias.  
The authors comment on the fact that surgical efforts may vary with age, cancer centre and 
those women who are more unwell are more likely to have less aggressive surgery and thus 
larger residual disease. 
 
Due to the heterogeneity of disease burden at presentation alongside patient factors, it 
becomes a clinical judgement to determine the most appropriate treatment strategy.  This is 
often a multidisciplinary decision considering radiographic opinion of staging CT images, 
diagnostic laparoscopic findings, co morbidities, patient’s wishes and surgical expertise of the 
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particular cancer centre.  Currently, there are no clinically useful biomarkers that predict 




Overall, 85% of women with ovarian cancer experience recurrence of their disease45.  After 
completion of primary treatment for ovarian cancer women are followed up in an outpatient 
setting by clinicians over 5 years.  Consultation involves eliciting symptoms of concern, 
physical examination and CA125 measurement in an aim to detect recurrence early.   
In women with an asymptomatic recurrence detected by a raise in CA125 the OV05/EORTC 
trial demonstrated no improvement in survival when chemotherapy was administered 
compared to waiting to treat in the presence of symptomatic disease.49 
 
1.1.6.1.  Surgery for recurrent ovarian cancer  
Those studies investigating secondary cytoreductive surgery demonstrated a significant 
morbidity with limited long term survival benefit.50, 51 Much like primary surgery, complete 
resection of the disease was the strongest prognostic factor for survival.50  The DESKTOP 
group of studies have created a score incorporating primary complete cytoreduction, good 
performance status and absence of ascites to predict likelihood of complete secondary 
resection.52, 53  DESKTOP III randomised women to surgery or chemotherapy for recurrence.  
It demonstrated progression free survival (PFS) was 19.6 months for women randomized to 
undergo surgery followed by chemotherapy, compared with 14 months in women who were 
randomized to receive only second-line chemotherapy (HR, 0.66).54  Overall, decisions 
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regarding management of recurrent disease is based on lengthy MDT discussions with a 
holistic approach to care. 
 
1.1.6.2.  Platinum resistant disease 
Occurrence of tumour progression during or within six months of primary treatment with 
platinum chemotherapy or those who lack response to first line treatment is known as 
platinum resistant disease55, 56.  Treatment options include additional surgery, non-platinum 
based chemotherapy, molecular targeted therapies such as PARP inhibitors for patients with 
BRACA mutations and anti-angiogenic inhibitors such as Bevacizumab.57 
 
1.1.7  Poly ADP ribose polymerase (PARP) inhibition  
Breaks in DNA can result in mutations and unregulated cell division.  Homologous repair 
comprises of a series of pathways that function to repair DNA double stranded breaks.58  
Homologous repair deficiency (HRD) can occur due to germline or somatic mutations of genes 
involved in the homologous repair pathway and is associated with cancer and cell death.58        
PARP (poly ADP ribose polymerase) proteins also play a role in DNA repair by binding to single 
strand breaks to initiate repair and therapies that inhibit PARP are amongst the most novel 
treatments for women with ovarian cancer.22  Tumours that have underlying homologous 
recombination repair deficiency (HRD) are more susceptible to PARP inhibition.59   
 
PARP inhibitors bind and trap to PARP 1 and PARP 2 on DNA at sites of single strand breaks 
which causes double strand breaks.  In cancer cells which are also HRD, these breaks are 
repaired by error prone pathways causing cell death.59, 60  This process of depletion of two 
molecules in a DNA repair pathway causing cell death is known as ‘synthetic lethality’.19, 22 
 11 
BRCA 1 and 2 genes play multiple roles in homologous repair19 and those tumours with BRCA 
mutation are consistent with HRD.  Although germline (15%) and somatic (8-9%) BRCA 
mutations are common in high grade serous cancer22, HRD occurs from mechanisms other 
than BRCA mutation and up to 50% of ovarian cancers have a mutation in a gene related to 
homologous recombination function.22, 61  Although BRCA 1 and 2 mutations are the most 
clinically relevant mediators targeted by treatments such as PARP inhibitors, the clinical 
application of these therapies is now much wider and PARP inhibitors therefore have a role 
in women without BRCA mutation. 
 
The Solo 1 trial has led to unprecedented changes to primary treatment for women with 
ovarian cancer.  Those women with advanced disease and BRCA mutation derived significant 
PFS benefit from maintenance olaparib vs placebo (median 41 month vs 13.8 months HR 0.30 
p=<0.001).36  Recent 5 year follow up data from this randomised trial has revealed that this 
benefit lasts beyond the 2 years of treatment with those women receiving olaparib (PFS 56 
vs 14 months).37 
 
Additionally another PARP inhibitor, niraparib, demonstrated an improvement in PFS and OS 
in both patients with and without BRCA mutation when given in first line treatment (PRIMA 
trial)62  and both olaparib and niraparib are licensed by the FDA (Food and Drug 
Administration) and EMA (European Medicines Agency) for first line monotherapy.   
In the recurrent disease setting, PARP inhibitors also improve outcomes for women.  Both 
olaparib (Solo 2 trial)63 and niraparib (NOVA trial)64 demonstrate improved PFS in women with 
recurrent disease.  Niraparib improved PFS from 5.5 to 21 months in those with BRCA 
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mutation although improvement was also seen in those with non BRCA cohort albeit more 
modest (3.9 vs 9.3 months).64  Furthermore Rucaparib (ARIEL 3 trial) significantly improved 
progression free survival in patients with platinum sensitive cancer in all groups of women 
irrespective of BRCA mutation status.65 
Olaparib received NICE (National Institute of Clinical Excellence) approval in 2019 for newly 
diagnosed ovarian cancer and BRCA mutation in the UK and Niraparib is available in England 
through cancer drugs fund. 
These advances in treatment for ovarian cancer from PARP inhibitors make it imperative that 
patient have counselling and access to BRCA testing at the point of diagnosis to allow for 
treatments to be started in the first line setting. 
 
1.1.8.  Conclusion 
 
It seems sensible in the light of high treatment morbidity, that focus on therapies that prevent 
recurrence and improve progression free survival would be both cost effective and beneficial 
and is the current target of research for treatment for ovarian cancer.  The role of 
angiogenesis in ovarian cancer development and progression is beginning to be understood 
and treatments that inhibit tumour angiogenesis have been developed and show promising 
improvements in PFS both after primary treatment and in the context of disease recurrence.  
The predominance for angiogenesis in particular tumours, optimal timing of angiogenic 
inhibitors and identifying which patients may benefit from these therapies are currently 
unanswered questions.  They are key priorities to ensure that the most effective and least 
morbid treatment is offered to an individual. 
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1.2.The role of angiogenesis in cancer 
 
In order for tumours to grow beyond 1-3mm66 and metastasise, new blood vessels must be 
formed to allow delivery of oxygen and nutrients.  This process is known as angiogenesis.  The 
process is controlled by pro and anti-angiogenic factors and is disordered in cancer.  When 
pro-angiogenic factors are dominant the tumour undergoes a process known as the 
angiogenic switch which leads to the formation of new vessels and tumour progression.67, 68 
Tumour vessels differ to normal vessels in that they are tortuous, often highly permeable and 
irregular.69  Angiogenesis in cancer is a complex process with multiple pathways involved.  
Sprouting from existing vessels, production of factors that destabilise the normal vasculature 
and formation of new blood vessels from precursor mesodermal cells are mechanisms by 
which tumour angiogenesis occurs.69-73  
 
There are multiple angiogenic activators that stimulate tumour angiogenesis.69 Metabolic 
causes such as hypoxia and genetic mutations such as activation of oncogenes or deletion of 





1.2.1.1.Vascular Endothelial Growth Factor 
The vascular endothelial growth factor family comprises a group of growth factors VEGF A-D 
and placenta growth factor (PIGF).  VEGF-A (VEGF) is a key molecule in the regulation of 
angiogenesis.  VEGF promotes the survival and proliferation of endothelial cells and increases 
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vascular permeability.66  VEGF activity is enhanced by hypoxia74, oncogenes75 and levels of 
VEGF have been widely demonstrated to be raised in tumours. 
 
The human VEGF gene is mapped to chromosome 6p21.3.76  The gene product is a heparin 
binding glycoprotein and there are multiple isoforms that make up the VEGF family, which 
are produced by alternative splicing from an eight-exon VEGF gene.76  Alternative exon 
splicing results in the generation of four main VEGF-A isoforms, which have respectively 121, 
165, 189, and 206 amino acids after the signal sequence is cleaved (VEGF121, VEGF165, 
VEGF189, VEGF206).77  VEGF189 and VEGF206 are bound to heparin-like structures in the cell 
surface or in the extracellular matrix, whereas VEGF121 is a freely diffusible protein.   
VEGF165 has intermediate properties in terms of heparin-binding and bioavailability.78-80 
VEGF acts by interacting with a set of cell surface tyrosine kinase receptors.81, 82  These 
receptors initiate signal transduction cascades in response to VEGF binding.  The receptors 
have an extracellular portion consisting of 7 immunoglobulin like domains, a single 
transmembrane spanning region and intracellular portion containing a split tyrosine-kinase.82  
The receptors consist of VEGFR-1 (Flt-1), VEGFR-2 (Flk-1) and VEGFR-3 (Flt-3).83-85  Whilst 
VEGFR-3 leads to lymphangiogenesis, VEGFR-1 and VEGR-2 are important in regulating 
angiogenesis and VEGFR-2 mediates most of the known cellular responses to VEGF.86, 87  
VEGFR-1 mobilises endothelial progenitor cells88, 89 and its soluble form sVEGFR1 appears to 










Preclinical studies have demonstrated an excess of endothelial cells and disorganised tubules 
in mice lacking VEGFR-1 and a sparsity of endothelial cells and inability to develop a 
vasculature in the absence of VEGFR-2.92, 93  On stimulation of VEGFR2, intracellular tyrosine 
kinase residues become phosphorylated and this results in downstream activation of 
signalling cascades including protein kinase C, RAS and ERK as well as P13-K/AKT/mTOR 
leading to endothelial proliferation, migration and survival.91, 94  Various mechanisms mediate 
VEGF expression including inflammatory cytokines interleukin 1 (IL-1), 6 and 8 and hypoxic 
inducible factors alpha (HIF-alpha).78 
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Despite some conflicting results, the majority of studies investigating serum VEGF levels have 
demonstrated an increase in those with malignant compared to benign ovarian tumours.95-97     
Additionally, high levels have been predictors of advanced disease, poorly differentiated 
tumours, increased metastasis, large volume of ascites and poor survival.87, 97-103. 
 
1.2.1.2.Other angiogenic factors in ovarian cancer 
There is complex interaction between the numerous growth factors mediating angiogenesis. 
Epidermal growth factor receptor, a member of the human epidermal growth factor (HER) 
family of tyrosine kinase membrane receptors is expressed on surface of epithelial cells.104  It 
has an extracellular domain (sEGFR) that is shed and released into the circulation.105  The main 
ligands for EGFR are epidermal growth factor (EGF), transforming growth factor-α (TGF-α) and 
amphiregulin.106  Overexpression of EGFR and has been associated with poor prognosis in 
ovarian and multiple other cancers104, 106-108 and levels of its ligands are significantly higher in 
cancer patients compared to controls.  Various tyrosine kinase inhibitors such as lapatinib and 
erlotinib targeting this pathway are licensed for treatment of lung cancer109 and it has been 
postulated that these biomarkers could be a potential maker of response to treatment for 
these patients.106  There is a sparsity of evidence however for both the significance of these 
biomarkers and treatment in ovarian cancer. 
 
Hypoxia inducing factor alpha (HIF-alpha) appears to upregulate VEGF expression in hypoxic 
conditions110 and correlates to microvessel density in the tumour.111 High levels of HIF-alpha 
in tumour have been linked to longer PFS in both ovarian and renal cell carcinoma.112, 113  
Additionally, levels of HIF-alpha have been correlated inversely with sensitivity of ovarian 
cancers to chemotherapy.112  
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Endothelin-1 acts as an angiogenic factor through its interaction with ET(A) receptor.  This 
receptor has found to be expressed in over 85% of ovarian tumours114 and high 
concentrations of ET-1 in ovarian cancer cells has been found in ascites.115  Binding of ET-1 to 
ET(A) modulates cell proliferation, apoptosis, migration, epithelial-to-mesenchymal 
transition, chemo resistance and neovascularization.116 
 
Interleukin 8 is a small chemotactic cytokine that induces neovascularisation.117  IL-8 is 
secreted by tumour cells to induce tumour growth and has a proangiogenic effect in ovarian 
cancer.118  IL-8 levels are raised in women in ovarian cancer119 high levels in tumour tissue, 
ascites and serum have been linked to poor prognosis.120  Similarly, Interleukin 6 (IL-6) 
mediates tumour growth and angiogenesis in ovarian cancer121 and high levels of IL in the 
serum and ovarian cancer tissue are associated with shorter OS and DFS.69, 122 
 
Amongst the largest group of receptor tyrosine kinase families is the Eph receptors.  There 
are 16 Eph receptors identified and they along with their ligands play a role in tumour 
angiogenesis.111  Specifically, high levels of EphB4 and B2 expression in ovarian tumours 
correlated with poor OS and may be an independent predictor of chemotherapy response in 
patients.123 
 
Horala et al. measured a panel of angiogenic markers in women with malignant ovarian 
tumour, benign tumours and healthy controls to ascertain their efficacy as a screening tool to 
detect ovarian cancer.124  Basic fibroblast growth factor (FGF), follistatin, hepatocyte growth 
factor (HGF), osteopontin (an extracellular structural protein) and platelet derived growth 
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factors AB/BB (PDGF-AB/BB) were significantly increased (p=<0.03) in those with malignant 
disease in comparison to the control group.124   
 
Platelet derived growth factor (PDGF) is another important growth factor involved in 
angiogenesis.  Platelet derived growth factors are a disulfide-linked dimers of two polypeptide 
chains.  Four different chains PDGF A-D have been identified.89  PDGFRs are expressed on 
pericytes; contractile cells that line and stabilise new endothelial cells to create stable tumour 
vasculature.89 
 
High levels of PDGF have been found in ovarian cancer cells and is related to disease 
progression.125  High serum levels of PDGF-AA and PDGF-BB have been associated with 
residual disease after primary cytoreductive surgery and have a prognostic significance in 
women with recurrent ovarian cancer who were treated with Bevacizumab.  It has also been 
suggested that PDGR plays a role in tumour evasion in anti-angiogenic treatment.126  
 
Fibroblast growth factor (FGF) affects endothelial cell migration, proliferation and is an 
important proangiogenic factor.127  There are over 20 FGF ligands and 5 receptors128 and FGF-
2, 3, 1 and 7 are expressed in ovarian cancer models.128-132  More specifically FGF 1 and 3 are 
associated with poor prognosis.129  It is likely that FGF, PDGF and VEGF work in synergism to 
stimulate tumour angiogenesis and high levels of various angiogenic markers correlate in 
various studies.87 
 
Angiopoietins 1 and 2 (Ang-1, Ang-2) are cytokines which contribute to tumour angiogenesis.  
Ang-1 and Ang-2 both bind to the tyrosine kinase reception Tie 2.97  Ang-1 stabilises blood 
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vessels by promoting adhesive interactions between endothelial cells and pericytes and 
smooth muscle cells and contributes to tumour dissemination and metastasis.133, 134  Ang-2 is 
an antagonist of Ang-1 and has a more prominent role in cancer.  In the presence of VEGF, 
Ang-2 stimulates tumour angiogenesis and destabilises the normal vasculature.135  High levels 
of Ang-2 have been demonstrated in hepatocellular and gastric cancer and associated with 
poor prognostic and advancing tumour stage.136, 137  In ovarian cancer, increased levels of 
VEGF produced by the tumour have been shown to increase expression of Ang-2 in the 
endothelial cells.138   
 
Raised serum levels of both Ang-1 and Ang-2 have been demonstrated in women with ovarian 
cancer compared to controls and elevated Ang-2 levels >2.7ng/ml was a significant predictor 
of poor OS and PFS.139 
 
Zhang et al found that VEGF induces Ang-2 transcription via VEGFR-2 and high levels of Ang-
2 were found in endothelial cells located in ovarian cancer tumours.138  A more recent study 
attached to the AGO-OVAR2.11 study investigating multityrosine kinase inhibitor sunitinib 
which targets platelet derived growth factor receptors (PDGRF) and VEGRs, in platinum 
resistant ovarian cancer attempted to assess molecular biomarkers to be used to 
demonstrate response to the treatment.140  It demonstrated a trend for prolonged PFS (8.4 
months vs 2.7 months p=0.089) with those women who had decreasing serum Ang-2 levels 
during treatment.  There was no significant benefit in prolonged PFS or OS demonstrated with 
the use of Sunitinib.140 
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Sallinen et al. demonstrated significant raised levels of Ang-1, Ang-2, VEGF and Ang-
2/sVEGFR-2, VEGF/sVEGR-2 ratios in women with ovarian cancer compared to controls. 
Elevated Ang-2, VEGF, VEGF/sVEGFR-2 ratio and low sVEGFR-2 levels were also predictors of 
poor OS and PFS in univariate survival analysis and all reached statistical significance.97 
 
Endoglin is a transmembrane receptor that is upregulated in proliferating endothelial cells.141  
A soluble form of endoglin has been detected in patients with pre-eclampsia and is raised in 
patients with colorectal and breast cancer.141  Sol-endoglin impairs endothelial cell 
proliferation and capillary formation and is also implicated in vascular resistance and been 
demonstrated to induce hypertension in vitro due to its effect on endothelial cell function.142   
 
In a series of 113 cases of ovarian cancer samples, a positive stain for p53 was associated with 
a complete response to treatment.143  Overexpression of p53 is associated with reduced TPS-
1, an inhibitory angiogenic factor.  Thrombospondin 1 (TPS-1) inhibits growth of new blood 
vessels144 and is regulated by p53.  Overexpression of p53 has been demonstrated in ovarian 
cancer cells and thus may indirectly influence angiogenesis.143 
 
 
1.2.2.Angiogenic inhibitor therapy 
 
The theory of anti-angiogenic medications to prevent tumour growth and metastasis was first 
postulated in 1971 by Folkman145 and has been the subject of intensive investigation since.  
The mechanism by which angiogenic inhibitors are effective is complex.  It seems obvious that 
preventing tumour angiogenesis thus depriving the tumour of oxygen and nutrients would 
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prevent tumour growth and spread.94, 145, 146  However, angiogenic inhibitors used as a 
monotherapy have not resulted in a significant improvement in outcomes in terms of overall 
survival.  In contrast when angiogenic inhibitors have been used in addition to chemotherapy 
regimens improved PFS has been demonstrated in not only ovarian cancer but colorectal, 
breast and renal cell carcinoma.94  Jain et al argues that angiogenic inhibitors in fact normalise 
tumour vasculature by stabilising the balance between pro and anti-angiogenic factors thus 
making the tumour more sensitive to chemotherapy.147 
 
The structure of blood vessels in tumour tissue are poorly formed, tortuous and lack a coat 
of pericytes.148  As a result, poor blood flow occurs leading to poor delivery of oxygen, nutrient 
supply and chemotherapy.   Inhibition of VEGF and subsequent normalisation of vasculature 
can improve this and thus increase efficacy of these drugs.149 
 
Pre-clinical studies have demonstrated that an angiogenic inhibitor Bevacizumab decreases 
tumour perfusion and micro vessel density in rectal cancer.150  Furthermore, when used with 
chemotherapy it increased tumour oxygenation and an increased uptake of chemotherapy 
was noted.151  This has led to the development of many studies to investigate the addition of 








1.2.2.1.Bevacizumab for ovarian cancer  
 
Bevacizumab is a recombinant humanised monoclonal IgG antibody that targets VEGF.  Its 
use as an angiogenic inhibitor has demonstrated benefit in patients when given as a 
maintenance treatment after primary treatment for ovarian cancer.  Inhibition of VEGFA has 
been demonstrated in pre-clinical studies to reduce ascites formation and inhibits growth of 
dissemination cancer.152   
 
Regarding first line treatment in ovarian cancer, Burger et al randomised patients with Stage 
III/IV ovarian cancer who had undergone debulking surgery to receive standard 
chemotherapy (control group), chemotherapy with the addition of Bevacizumab 
(Bevacizumab initiation group) or chemotherapy plus bevacizumab which continued alone for 
an additional 14 cycles (Bevacizumab throughout group).153  They demonstrated a lower 
hazard of progression or death in the Bevacizumab throughout group (HR 0.717 [CI 0.625-
0.824 ]P= <0.001).  A significant increase in PFS of 3.8 months was seen in this group once 
adjusted for various other prognostic factors (14.1 months vs 10.3 months p<0.001).  There 
was no significant difference in progression free survival between the control and 
Bevacizumab initiation group.  There was no difference in OS between the groups.153 
 
The study reported an increased risk of grade 2-3 hypertension (22.9% in Bevacizumab 
throughout group vs 7.2% controls p= 0.05) and GI events including perforations (2.6% vs 
1.2%) although there was no reduction in quality of life reported in those treated with 
Bevacizumab.153   
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ICON are a group of trials by the Gynaecologic Cancer InterGroup (GCIG) designed to 
determine the most effective treatments for ovarian cancer.  The ICON 7 trial has shown 
similar results of the addition of Bevacizumab to standard treatment in a wider population as 
this included women with early stage disease.35  A lower hazard of progression or death (HR 
0.81(CI 0.70-0.94) p= 0.004) was seen in women with maintenance Bevacizumab treatment 
for an additional 12 cycles.  An increase in PFS after 42 months was shown compared to those 
in the standard chemotherapy group (24.1 months vs 22.4 months).  Furthermore, these 
benefits were greater in those women at higher risk of disease progression where 3.6 month 
improvement in PFS was seen (14.5 months vs 16.1 months HR 0.73 p=0.002).35 Most 
significantly, improvement in OS of 7.8 months (28.8 months vs 36.6 months HR 0.64 (CI 0.48-
0.85) p=0.002) was seen in those women most at risk of progression: stage 4 or residual 
disease after surgery.35  The results of these trials led to Bevacizumab being approved by the 
EMA in first line treatment in 2011 and is available in England via Cancer drugs fund. 
 
ICON 8b is an ongoing international randomised (1:1:1 ratio), three arm, three stage phase III 
trial designed to evaluate the safety and efficacy of bevacizumab in combination with dose 
dense, dose fractionated chemotherapy compared to either strategy alone for first line 
treatment of ovarian cancer.154  Bevacizumab continues alone as a maintenance therapy 11 
months after primary treatment.  Primary outcome measures are OS and PFS.  Secondary 
outcomes will include comparative toxicity, impact on quality of life and cost effectiveness of 
the additional treatment.   
 
In regards to second line treatment in ovarian cancer; similar efficacy of the addition of 
Bevacizumab to standard chemotherapy was initially demonstrated by Burger et al where 
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increased progression free and overall survival was seen after the addition of Bevacizumab in 
patients with persistent or recurrent ovarian cancer.155  This effect was echoed in patients 
with platinum resistant disease although significant side effects of hypertension and GI 
perforation occurred in around 10% of patients.  Median progression free survival was 
superior (12.4 vs 8.4 months) for those treated with Bevacizumab (HR 0.48 p= <0.001).156  
 
The Aurelia trial also demonstrated an improvement in PFS in women with platinum resistant 
ovarian cancer when Bevacizumab was added to standard chemotherapy regime (6.7 vs 3.4 
months HR 0.48 p=<0.001).157 
 
Despite these multiple studies demonstrating an improved PFS, albeit by only a few months, 
there has been no evidence of improvement in OS.  There was vast heterogeneity of women 
included in these studies in terms of disease stage, treatment and surgical outcomes.  There 
also remains debate about the optimal length and dose of maintenance Bevacizumab 
treatment and there is no method of selecting patients likely to benefit from the addition of 
Bevacizumab to current treatment of chemotherapy. 
 
1.2.2.2.Alternative angiogenic inhibitors in ovarian cancer 
 
Cediranib is an oral tyrosine kinase inhibitor which targets all VEGFRs.  In relation to recurrent 
disease ICON 6 demonstrated an improved PFS (HR 0.56 [CI 0.44-0.72] P<0.0001) of women 
given Cediranib alongside chemotherapy with maintenance treatment after follow up of 19.5 
months (8.7 months vs 11.0 months).158  This benefit was greater for those who continued 
Cediranib for maintenance compared to those who received it only alongside chemotherapy.  
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More follow up data to investigate impact on OS is awaited.  Tolerance for the drug however 
during maintenance treatment was poor due to increased toxic effects namely diarrhoea, 
hypothyroidism and voice changes.158 
 
Nintedanib is an oral multikinase inhibitor of VEGR, FGFR and PDGFR.  LUME-OVAR1 trial 
involving the addition of nintedanib to carboplatin/paclitaxel chemotherapy resulted in a 
statistically significant prolongation of PFS compared with placebo plus chemotherapy (HR 
0.84 (95% CI 0.72, 0.98) p = 0.0239). Median PFS was 17.2 months in the nintedanib arm and 
16.6 months in the placebo arm.159  
 
Pazopanib is an oral, multikinase inhibitor of VEGFR -1/-2/-3, PDGFR -α/-β.  When pazopanib 
was used as maintenance therapy in patients with ovarian cancer whose disease did not 
progress during first-line chemotherapy had a median prolonged PFS of 5.6 months compared 
to those treated with placebo (HR 0.77 (95% CI 0.64 to 0.91) p=0.0021). However, there was 
no demonstrable increase in OS.160 
 
Trebananib is a peptibody that binds to Ang1 and Ang-2 to prevent interaction with Tie -2 
receptor.  TRINOVA-1 study involved the addition of trebananib to chemotherapy for women 
with recurrent ovarian cancer.  Trebananib significantly improved median PFS (HR 0.85 [CI 
0.74-0.98] P=0.024) compared with placebo (12.5 versus 10.9months) but had no significant 
impact on OS.161  
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In summary there are many large studies as summarised in Table 1.2 that have now 
investigated the benefit of a number of angiogenic inhibitors although none of these have 
had an impact on OS and carry additional morbidity to standard treatment.   
 
The NHS has finite funds and the economic impact of the routine use of these therapies must 
be considered.  The cost of Bevacizumab per month is £1800 per patient.  It has been 
stipulated in the literature that the additional annual treatment costs for even 50% of new 
patients diagnosed each year with ovarian cancer will cost over £20M in the UK.162   
 
As these drugs have shown no benefit in increased OS it is imperative that these therapies 
are targeted to those who will benefit and a biomarker that may predict response to 














Table 1.2.  Angiogenic factors in cancer treatment 
Antiangiogenic 
inhibitor 
Mechanism of action Setting Trials 
Bevacizumab Humanised monoclonal antibody 
directed against VEGFA.  Binds and 
neutralises VEGFA. 
Adjuvant in primary 
ovarian cancer 
 
GOG 218 (2011)153 
ICON 7 (2011)35 
Recurrent ovarian cancer OCEANS (2012)156 
Aurelia (2014)157 
Sorafenib VEGFR tyrosine kinase inhibitor Recurrent ovarian cancer Matei et al 
(2011)163 
Sunitinib VEGFR tyrosine kinase inhibitor 
PDGF tyrosine kinase inhibitor 
Recurrent ovarian cancer Biagi et al (2011)164 
AGO-OVAR2.11 
Baumann et al 
(2012)165 
Cediranib VEGFR tyrosine kinase inhibitor Maintenance recurrent 
ovarian cancer 
Matulonis et al 
(2009)166 











Kristensen et al 
(2014)167 




Friedlander et al 
(2010)168 
AGO OVAR 16 
(2014)160 
AMG 386 Pedtide-Fc fusion protein.  
Prevents interaction of Ang-1/2 




et al 2014)161 





1.3.Microvessel density as a surrogate marker of angiogenesis in the tumour 
 
Microvessel density (MVD) of the tumour is used as a surrogate marker of angiogenesis.169  
MVD in tumours has been studied to ascertain the relationship of angiogenesis with tumour 
progression and areas of increased MVD in tumours has been demonstrated to have an 
adverse impact on prognosis and are associated with metastasis.170 
 
Numerous studies in a variety of cancers have demonstrated that tumour MVD is a predictor 
of PFS.171, 172  Alvarez et al demonstrated improved median survival when MVD count was <10 
(7.9 years vs 2.7 years p=0.03).  This was still the case when adjusted for stage, grade of the 
tumour and age of the patient.171  There have been several further studies in ovarian cancer 
that have demonstrated an inverse relationship between MVD and both PFS and OS and 
demonstrated that high grade and stage tumours were also associated with increased MVD.69, 
171, 173-180  Lastly a meta-analysis of 22 studies investigating MVD and prognosis in ovarian 
cancer concluded that high MVD measured with CD34 antibody was associated with poor OS 
(HR 1.83 (CI 1.33-2.35) and PFS (HR1.36 CI 1.06-1.66).181   
 
1.3.1.Methodology of MVD 
Methods to quantify tumour angiogenesis by MVD are well established. Sections of tumour 
are stained immunohistochemically for various endothelial markers such as CD34181-183 , 
CD31181, 184  and 117/13) or factor VIII.181  The choice of antibody in studies to measure MVD 
varies.  CD34 and CD 31 are glycosylated transmembrane proteins that are expressed on 
immature haemopoietic cells and on luminal endothelial cells and have a higher specificity 
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and sensitivity for detection of tumour angiogenesis compared with factor VIII and are the 
most widely used.185   
 
Once stained Weidner’s method is most commonly used to measure MVD.  Areas of high 
microvessel density named ‘hot spots’ are ascertained at low power (x200 magnification) and 
then vessels in these areas are counted at high power ( x400 magnification) through a 
Chalkley count.186, 187    This involves a 25 point grid placed onto a scanned image and all points 
coinciding with marked vessels are counted.187 
 
An alternative method for MVD analysis involves systematic, uniform, random sampling 
(SURS) of up to 10 regions of interest (ROI) from the whole slide images in an attempt to avoid 
observer dependent sampling variation.188, 189  Manual or computer assisted counting 
methods can be used for quantification.188-190  The number of CD31 or 34 positive vessels 
/mm2 of tumour tissue thus indicates the MVD. 
 
1.3.2.  Microvessel density as a biomarker of angiogenic inhibitors  
 
Although MVD is established as a prognostic factor for untreated ovarian cancer, until 
recently it was not demonstrated to be a viable biomarker of response to treatment.  It seems 
reasonable that if MVD is a surrogate marker for angiogenic activity in the tumour then it may 
be a useful biomarker for both predicting and monitoring response to anti angiogenic activity.   
MVD in cancer models has been shown to decrease after anti angiogenic therapy due to 
apoptosis of tumour endothelial cells69 thus the use of MVD as a biomarker of response to 
treatment with these therapies is possible. 
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A recent retrospective biomarker analysis of the GOG -0218 trial where patients with 
incompletely resected stage III or stage IV ovarian cancer were randomised to receive 
Bevacizumab alongside chemotherapy and for maintenance has been published.188  The 
authors revealed that the effect of Bevacizumab on PFS was improved in both women with 
high and low MVD but was greater in patients with higher (above median) MVD compared to 
those with low MVD.(HR 0.40 in high MVD (0.29-0.54) vs 0.80 in low MVD CI 0.59-1.07).  In 
the subgroup of women with higher MVD, there was also a gain in OS seen and no benefit in 
OS to those with low MVD. (HR 0.67 (CI 0.51-0.88 in high MVD vs HR 1.10  (CI 0.84-1.44) in 
low MVD). 188 
There has been no assessment of MVD pre and post chemotherapy and its relationship with 
chemotherapy response scores (CRS), nor in association with the use of angiogenic inhibitors.   
 
1.3.3.Alternatives to micro vessel density 
 
Due to some inconsistencies with the value of MVD in some studies and prediction of 
response to angiogenic inhibitors, there is a growing need to establish an alternative method 
that measures immature, newly developing` vessels as a measure of active tumour 
angiogenesis. 
 
It has been argued that quantification of vessels that are immature may be more specific in 
assessing tumour angiogenesis.  These new immature vessels require VEGF-A signalling for 
survival and are thus the targets of antiangiogenic inhibitors.135, 188, 190, 191  The ratio of Ang-
2:Ang-1 as discussed earlier may go some way to reveal this but other markers associated 
with the formation of new vessels are being investigated. 
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Stabilisation of newly formed vessels is a key factor in successful tumour angiogenesis.  
Covering of endothelial cells by pericytes is part of this process.  Pericytes are contractile cells 
that line endothelial cells and are important for vessel wall stability and endothelial cell 
survival.192  PDGFR ß and alpha SMA are expressed on pericytes and have been shown to have 
a role in metastasis.193  Covigno et al recently demonstrated that high expression of PDGF ß 
in perivascular cells in ovarian tumours in women who underwent primary debulking surgery 
was significantly associated with shorter OS.194  Alpha SMA expression produced by pericytes 
was also increased.  These findings have been reiterated in colorectal and renal cell, the later 
also demonstrating a positive correlation between increased PDGF ß expression in advanced 
stage of disease.193, 195 
 
Resistance to angiogenic inhibitors in other cancers such as melanoma has been postulated 
to be due to tumour vessel stabilisation and normalisation by coverage of mature 
pericytes.196  PDGF ß and alpha SMA as markers of pericytes coverage are therefore 
potential biomarkers to target angiogenic therapies more suitably. 
 
1.3.4.  Proliferative markers in cancer  
 
Unregulated cellular proliferation is a fundamental hallmark of cancer behaviour.  Loss of 
response to proliferative control distinguishes cancer cells from normal and leads to invasion 
and metastasis.  Ki67 is a marker of cell proliferation.  It is localised in the nucleus of the cell 
and is expressed at all stages of the cell cycle apart from the rest phase (G0).  Pathologists 
usually describe Ki67 as a percentage of nuclei that stain positive and typically high-grade 
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serous carcinoma of the ovary is associated with a high (>40%) and diffuse pattern of staining 
for Ki67.197 
 
There is a lack of consensus regarding Ki67 and its association with outcomes or role as a 
biomarker to target treatment and studies show conflicting results.   Some investigations 
suggest that high Ki67 is associated with reduced OS and PFS due to high proliferative nature 
of the tumour.198  Nonetheless others have demonstrated improve PFS due to improved 
sensitivity of the tumour to chemotherapy.197  A large cohort of 318 patients showed a low 
Ki67 (<40%) was significantly associated with resistance to platinum based chemotherapy ( 
HR 2.85, 95% CI 1.43–5.98, P < 0.001) and reduced OS (HR 1.74, 95% CI 1.38–5.01, P = 
0.003).197 
 
1.4.Biomarkers of angiogenesis  
 
A biomarker is defined as any substance, structure, or process that can be measured in the 
body or its products and influence or predict the incidence of outcome or disease.199  The 
marker CA125 (a glycoprotein) is currently widely used as a monitoring tool in ovarian cancer 
treatment in relation to chemotherapy and relapse although early treatment based on rising 
CA125 in the absence of symptoms is controversial.200 
 
At present there is no biomarker in clinical use with relation to angiogenesis in cancer.  As 
discussed, the process of tumour angiogenesis is multifactorial and complex making it difficult 
to identify a specific maker.  Nonetheless identification of a reliable biomarker is paramount 
for many reasons.  Identification of those patients who will benefit from targeted therapies, 
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monitoring response to treatment and identifying those at risk of adverse events are essential 
for achieving a personalised medicine approach to cancer treatment and cost effectiveness 
for the NHS. 
 
Many biomarkers are assessed after starting treatment or are studied in recurrent disease 
and are therefore unhelpful in determining suitable patient selection for treatment.  Robust 
predictive markers for response to treatment or for appropriate patient selection are lacking 
in ovarian cancer.   
 
1.4.1.Biomarkers in response to angiogenic inhibitor therapy 
 
1.4.1.1. The role of VEGF as a biomarker 
There are many studies that have measured VEGF to help predict outcome of Bevacizumab 
treatment with conflicting results.  A large meta-analysis of 1816 patients confirmed that pre-
treatment VEGF levels were prognostic rather than predictive of response to treatment in 
patients treated with Bevacizumab for colorectal, lung and renal cell carcinoma.201  However, 
sVEGFR1 levels have been shown to be inversely related to outcome of treatment.202  In those 
studies which have measured a specific VEGF isoform VEGF121, high baseline levels have 
consistently demonstrated an association with improved PFS and OS after treatment with 
Bevacizumab.202-205 
 
There are a few studies which have monitored VEGF in women treated with antiangiogenic 
inhibitors.  2 studies demonstrated that a low baseline VEGF was associated with increased 
response and survival, one of these studies showed a significant association (60% increased 
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chance of response when VEGF was below median vs 0% response above median 
p=>0.0007).103, 206  However, both  studies looked at patients with recurrent disease and 
included less than 40 patients.  In a study of 60 patients again with recurrent disease, high 
VEGF levels and increased MVD at baseline were associated with decreased OS.  This study 
also measured thrombospondin-1 (a glycoprotein and inhibitor of angiogenesis) where high 
levels were associated with decreased OS and PFS.100 
 
A retrospective analysis of the GOG 0218 trial found that tumours with a high expression of 
tumour VEGF-A were found to have an increased OS advantage compared to low levels of 
expression HR 0.72 (CI 0.56-0.94) in high expression vs HR 1.06 (CI 0.81-1.39) in low 
expression.207  Since the primary target of Bevacizumab therapy is VEGF-A, it makes sense 
that tumours expressing high levels of VEGF-A may be the most sensitive to its effect. 
 
1.4.1.2. VEGF isoforms (VEGF165b) 
VEGF pre-mRNA undergoes alternative splicing to produce both pro angiogenic (VEGFxxx) and 
anti angiogenic (VEGFxxxb) families of isoforms.208  Serine-arginine protein kinase 1 (SRPK1) 
is a kinase that phosphorylates SR- proteins and modulates their activity.209  
 
A study involving patients with metastatic colon cancer demonstrated that only those 
patients where low levels of VEGF165b were expressed in the tumour gained benefit from 
Bevazizumab.210  The balance of VEGFxxx:VEGFxxxb is important in regulation of tumour 
angiogenesis208 and a study which demonstrated that immuno-histochemistry (IHC) staining 
of tumours for VEGFxxxb predicted disease free survival in patient treated with Bevacizumab 
and chemotherapy.211  Bunni et al demonstrated that circulating VEGFxxxb levels correlated 
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to IHC staining and thus could be a surrogate marker to help stratify patients with colorectal 
cancer patient for Bevazizumab.208  Furthermore, in ovarian cancer reduction in SPRK1 
expression was associated with reduced cell proliferation rate and enhanced sensitivity to 
cisplatin suggesting a potential new target for ovarian cancer treatment.212 
 
VEGF165b is a spliced variant and differs from VGEFA in 6 amino acids at the carboxy terminal 
3 end.  This switch from argine to aspartic acid and lysine is postulated as the mechanism 
behind the change in function to an antiangiogenic variant due to the different function and 
binding to VEGF R 2.213  Recently Ganta et al has demonstrated that VEGF165b inhibits VEGF 
receptor 1 related Signal Transduction and Activator of Transcription 3 (STAT3) signalling thus 
causing a decrease in VEGF A mediated activation of VEGFR1 resulting in reduced 
angiogenesis.214, 215  STAT3 pathways have been shown to be important in metastasis and 
resistance to cancer treatments.  This suggests that VEGF165b may pay an important role 
which so far has not been investigated in ovarian cancer.   
 
1.4.1.3. Alternative serum and tissue biomarkers 
In relation to serum and plasma biomarkers which are inevitably more convenient to obtain, 
further retrospective analysis of pre-treatment plasma in the GOG-0218 trial were also 
investigated.   Authors demonstrated that IL6 was predictive of therapeutic benefit in terms 
of prolonged PFS, HR 0.76 (CI 0.48-0.94) for high levels vs HR 0.87 (CI 0.70-1.08) for low levels 
and OS HR 0.79 (CI 0.65-1.16) for high levels vs HR 1.07 (CI 0.84-1.37) for low levels from the 
addition of Bevacizumab in addition to standard treatment.  IL6 and osteopontin were 
negative prognostic markers for both PFS and OS (p=<0.001).216  High Ang-2, IL-8 and low 
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VEGFR2 were also demonstrated to be poor prognostic factors in the retrospective 
analysis.216   
A translational retrospective analysis of 92 patients enrolled in the ICON 7 study investigated 
15 circulating angio-biomarkers in order to predict response to Bevazicumab.   Changes in Tie 
2 and Ang 1 were restricted to those receiving Bevacizumab and although levels did not 
predict response to treatment, a rise corresponded to progression of disease.217     
In patients with recurrent disease who were treated with Bevacizumab in addition to standard 
chemotherapy patients genotyped for the A/A or A/T for the IL-8 T-251A gene polymorphism 
had a lower response rate to treatment compared to those who were homozygous.218  
Authors have postulated that this could be a potential biomarker for response but this has 
not been further validated.94, 218  High baseline levels of PDGF-BB and FGF2 are associated 
with lower OS in women treated with Bevacizumab in recurrent ovarian cancer as 
demonstrated by Madsen et al.219  Levels of these markers were collected after each cycle of 
treatment but there was no significant difference in the levels detected in those responding 
to treatment compared to those with refractory disease.219 
 
No trial has monitored these angiogenic markers throughout treatment as yet and there is a 
need to ascertain trends to help predict response. 
 
In normal tissues endothelial cells divide infrequently however rapid proliferation occurs 
during angiogenesis.69  Levels of circulating endothelial cells are raised in patients with cancer 
compared to control.69  Both mature circulating endothelial cells (CEC) and circulating 
endothelial progenitor cells (CEP) which are released from the bone marrow under VEGF 
influence have been identified.  The use of antiangiogenic therapy reduces the amount of 
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CEPs220 which is further reflected in reduction of vascularity in the tumour.  Additionally, 
levels of CEPs have been shown to fall with the use of metronomic chemotherapy221 where 
chemotherapy agents are given at shorter intervals at a lower dose suggesting these methods 
of chemotherapy administration has a negative effect on angiogenesis.  This is currently being 
investigated in ovarian cancer as part of the ICON8b trial. 
 
Circulating endothelial cells (CEC) and circulating progenitor cells (CEP) have been found to 
be elevated in women with ovarian cancer and are a potential dynamic biomarker.168, 222  High 
levels of CEP are associated with advanced stage and poor prognosis.222  VEGF has been 
shown to mobilise CECs and levels fell in a preclinical study where ovarian cancer mouse 






Multiple clinical and molecular biomarkers have been investigated in other cancers such as 
renal cell carcinoma where the use of angiogenic inhibitors is common for primary and 
recurrent disease.223  So far only clinical related biomarkers, the Heng criteria224 are used to 
risk stratify and counsel patients.  Heng et al demonstrated that pre-treatment low 
haemoglobin, raised corrected calcium, low performance status, raised neutrophil and 
platelet counts were associated with lower OS for patients treated with angiogenic 




There are known side effects as a result of the use of antiangiogenic inhibitors, the most 
common being hypertension.  There have been studies in patients with renal cell carcinoma 
that have demonstrated a link between treatment induced hypertension and a higher 
response rate and improved PFS after treatment with antiangiogenic inhibitors including 
Bevacizumab and Sunitinib.226-230 
 
Hypertension may represent a biomarker of tumour response in other cancer sites.231  In a 
small cohort of patients with colorectal cancer treated with Bevacizumab, partial remission 
was seen in 75% of patients who developed hypertension compared to 32% of those who did 
not (p=0.04).232  Similar findings have also been seen in breast cancer treatment where 
women who developed hypertension had an improved OS (38.7 vs. 25.3 months, p=0.002).233 
 
A small study has linked a reduction in skin capillary density (SCD) associated with 
treatment234 induced hypertension thus it is a reasonable hypothesis to consider that SCD 
may be an independent clinical biomarker of response to treatment with antiangiogenic 
inhibitors.  Whether it can also be used to predict prognosis or useful to target treatment with 
antiangiogenic inhibitors is also an interesting unanswered question. 
 
The role of molecular biomarkers in ovarian cancer is complex.  The ultimate aim of 
understanding the relationship between various markers and prognosis is to provide a 









The number of capillaries per unit of skin is defined as skin capillary density (SCD).  Assessment 
of SCD is a non invasive efficient technique that is easily accessible and requires a minimal 
amount of training.  It is an easily repeatable measure that can be collected in the outpatient 
setting and is well tolerated by patients. 
 
1.5.2.Factors that affect skin capillary density 
 
At present there is no agreement on a value for ‘normal’ capillary density in a healthy 
individual.  Due to the variance in some methodological techniques in studies it is difficult to 
be certain.  Nonetheless many studies have reported no statistical difference in SCD between 
children and adults, white and non-white populations and males and females.235  There is 
evidence however that capillary density decreases as part of the normal aging process in line 
with reduction of angiogenic factors such as VEGF, FGF and Angiopoietins.236, 237 
 
Certain disease states have also been shown to affect SCD.  Foremost, most work has been 
conducted in patient with rheumatological skin conditions to ascertain SCD is a biomarker 
that may predict onset of disease and response to treatment.237  Well recognised changes in 
the morphological appearance of the capillaries occur in conditions such as systemic sclerosis 





Capillaries are visualised by capillary microscopy or capillaroscopy which provides a 2D image 
of a 3D network of capillaries.  The number of capillaries are then counted to provide a skin 
capillary density. 
 
A capillary microscope in combination with a computer screen allows high contrast images 
that can be frozen or recorded.  The capillary microscope is mounted on a focusing block 
which is attached to an arm that allows the microscope to move up and down and back and 
forth over the patient’s skin.   
 
A light sensitive black and white camera is placed over a lens system and the skin illuminated 
by a 50 or 100W mercury vapour light.  The emission spectrum of mercury vapour is similar 
to the absorption spectrum of haemoglobin (370-450nm) so blood cells appear as black dots 
on the screen.  A green filter enhances the contrast to allow better interpretation of the 








Images are best achieved with the lens at 90 degree angle to the patient skin.  Due to the 
magnification small movements in the patient can distort images thus the patient’s finger is 
immobilised in a support.  A thin layer of oil is placed over a central dot that is to be examined 
marked on the dorsum of the middle finger of the left hand.  The oil prevents scattering of 
light to improve the image.235  In order to calculate SCD, four 1mm2 microscopic fields centred 
around an ink spot are recorded for 2 minutes continuously.  A video can be recorded for each 
quadrant with focusing level adjusted throughout to capture all capillaries and then capillaries 
counted during video replay in each quadrant and mean taken to calculate the SCD.  
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Capillaries counted at rest must be perfused and this count is known as the functional count.  
In some conditions, not all capillaries may be perfused, hence they must be filled in order to 
provide a structural count.  To achieve this venous occlusion is provoked at the base of the 
finger using a sphygmomanometer cuff at 60mmHg for 2 minutes then the same area 
recounted.  In healthy individuals the increase in capillary density is 12-18%.237  Functional 
rarefaction is thought to be the first step in the development of structural rarefaction as 
persistent non perfusion will lead to involution and irreversible loss of capillaries239 thus both 
measurements are important to consider.  This standardised method of measuring skin 
capillary density is well documented in the literature and the inter and intra observer 




Skin capillary density has been shown to decrease (capillary rarefaction) in patients with 
hypertensive disease compared to normotensive patients or those with well controlled and 
treated hypertension.237, 242  It has been demonstrated that the reduction in SCD is structural 
due to the absence of capillaries rather than functional non perfusion of them.242  This 
decrease is thought to precede the onset of hypertension and young individuals with a familial 
predisposition to hypertension have been found to have structural capillary rarefaction prior 
to developing hypertension themselves.243, 244 
 
Furthermore, this microvascular rarefaction has been demonstrated in women in pre-
eclampsia compared to normotensive pregnant controls.245  In fact capillary rarefaction was 
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identified to be a prognostic marker of pre-eclampsia, again preceding the onset of 
symptoms.246  
 
Insufficient angiogenesis has been suggested as a possible mechanism for capillary 
rarefaction but associations between angiogenic markers such as VEGF and capillary density 
have yet to be fully addressed.  In a preclinical study of rats, capillary density in striated muscle 
and heart was increased along with VEGF levels after prolonged exposure to hypoxia, thus 
reaffirming the effect of HIF-alpha on angiogenic factors such as VEGF.  Furthermore, the 
increase in capillary density was associated with normalisation of blood pressure in pre-
hypertensive rats.247  There is also evidence that chronic VGEF inhibition causes capillary 
rarefaction in preclinical models.  These effects in capillary regression are seen as early as 24 
hours after initiation of VEGF inhibitors.231 
 
It is clear therefore that skin capillary density is a dynamic variable that not only may be a 
causative factor in the disease process but may alter in response to pathology.  Skin capillary 
density may also act as a surrogate marker of angiogenic activity. 
 
1.5.5.Skin capillary density as a marker of disease 
 
Capillary density impacts on the total resistance of the capillary bed and thus capillary 
pressure.237  Capillary pressure is vital to tissue fluid homeostasis and trans capillary 
exchanges.237  It is well recognised that clinical presentation of ovarian cancer is 
heterogeneous with some women presenting with massive volumes of ascites.  Additionally, 
post-operative recovery courses vary considerably.  The assessment of SCD at presentation 
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and post operatively in relation to these clinical aspects may provide an insight into the 
microvascular status that may then help to predict those more at risk of post operative 
complications. 
 
A recent study has demonstrated an association between skin capillary rarefaction and the 
presence of albuminuria.248  This association was present after control for confounding 
variables such as diabetes and cardiovascular risk factors.  Although the assumption that skin 
capillary rarefaction is a reflection of the rarefaction in the kidney (a reason for the 
development of albuminuria)248 was recognised as a limitation it will be interesting to see 
whether SCD may also be associated with the presence of ascites and post-operative 
complications occurring due to increased capillary permeability and hypalbuminaemia.   
We have seen that SCD reduces with age due to the reduction in angiogenic factors so it can 
be argued that capillary density assessed in the skin may alter as VEGF alters throughout the 
cancer journey. 
 
A common side effect to angiogenic inhibitor therapy is hypertension.  The mechanism by 
which this occurs is not fully understood but 9-16% of patients treated with bevacizumab 
develop grade 3-4 hypertension.249 
 
It has been postulated that hypertension is a result of reduction in structural skin capillary 
density.249  Additionally, this rarefaction may be the cause of bevacizumab induced enteric 
perforations.250  A small study of 16 patients with metastatic renal cell carcinoma treated with 
an angiogenic inhibitor sunitinib had a significant decrease in skin capillary density associated 
with rise in blood pressure.234  This effect was reversible once the therapy stopped.  An 
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additional two small studies in patients with metastatic colorectal and breast disease found a 
decrease in SCD from baseline after 6 months of treatment angiogenic inhibitors and, with 
the effect reversing after cessation of treatment.249, 251 
A study of 37 patients with colorectal cancer receiving Bevacizumab recently demonstrated a 
reduction in skin capillary density during treatment.  There was no association with capillary 
rarefaction and response to treatment and the authors were not able to demonstrate 
correlation to hypertension.252 
In animal models, regression and apoptosis of endothelial cells leading to reduction in 
capillaries has been demonstrated after VEGF inhibition and it may be that similar 





Ovarian cancer is a complex diverse disease with a poor survival rate and complex treatment 
that carries significant morbidity.  The role of angiogenesis in ovarian cancer progression is 
well recognised and the area of research into angiogenic inhibitors as additional therapies is 
novel and exciting.  However, none of these treatments have demonstrated a survival benefit 
as yet and carry potential serious complications and high economic cost to the NHS.  The era 
of personalised medicine is developing and biomarkers are needed to target these treatments 
to those who will benefit at the optimal time. 
 
There has been no work as yet investigating SCD and angiogenic markers in cancer patients.  
As we have discussed, hypertension is a consequence of angiogenic inhibitors and potential 
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marker of response.  We have established that reduction in SCD occurs prior to the clinical 
development of hypertension thus it is reasonable to hypothesise that SCD may be the first 
thing to change in response to angiogenic inhibitors. 
 
Since many complications from bevacizumab treatment carry high morbidity and mortality, 
monitoring of response to allow early prediction of complications and therefore early 
intervention with a simple non-invasive measurement is appealing.  Furthermore, 
Bevacizumab is used in other malignancies and in the palliative setting hence the potential 

















1.6.  Hypothesis 
After consideration of the literature I have constructed the following hypotheses that I aim to 
address in my thesis. 
• Skin capillary density is a surrogate marker of angiogenesis 
• Skin capillary density reduces as a result of cancer treatment 
• Capillary rarefaction occurs with Bevacizumab treatment and correlates with change 
in blood pressure 
• Skin capillary density can predict response to treatment and cancer outcomes 

















I will now address the following aims in my subsequent chapters to address my hypotheses. 
• To identify changes in skin capillary density throughout treatment in ovarian cancer 
• To identify changes in angiogenic factors throughout treatment in ovarian cancer 
• To identify any association between skin capillary density and angiogenic factors 
• To investigate whether SCD at baseline predicts OS, PFS or surgical cytoreduction 
• To investigate whether the change SCD before and after 3 cycles of treatment can 
predict surgical cytoreduction or surgical morbidity in women undergoing 
neoadjuvant chemotherapy 
• To investigate whether tumour proliferation and vascular markers at baseline or at 
surgery can predict OS, PFS  
• To investigate whether tumour proliferation markers at baseline or at surgery can 
predict surgical cytoreduction, post-operative complications and response to 
chemotherapy (radiological CT response and histological chemotherapy response 
score) 
• To investigate the longitudinal changes in tumour proliferation and vascular markers 
after chemotherapy 
• To investigate the association between tumour vascular markers and skin capillary 
density 
• To assess the change in SCD in a specific population of patients on anti angiogenic 
therapy 
• To assess the effect of anti angiogenic therapy on blood pressure and association with 
skin capillary density 
• To assess the prognostic role of SCD in patients on Bevacizumab treatment 
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Chapter 2.  Methods 
 
2.1.  Study design and population 
 
2.1.1.  Study design 
 
This was a prospective longitudinal cohort study conducted over a 2-year period.  Ethical 
approval was granted in 2016. (Appendix 1). 
 
2.1.2.  Study setting 
 
Women were recruited from the primary cancer centre, St Michael’s Hospital, University 
Hospitals Bristol and a secondary site Weston General Hospital.  Patients were recruited from 
November 2017 until May 2018 and were followed up until January 2020. 
 
2.1.3.  Population 
 
During the recruitment period, I attended weekly Multidisciplinary Meetings where new 
patients were discussed and screened cases for suitable participants.  I approached women 
who were suspected of having a high-grade serous carcinoma and discussed the study and 
provided patient information leaflets.  If they were agreeable, I contacted them after 1 week 
over the telephone to see if they would like to participate.  I then met these women at their 
new patient chemotherapy talk or pre-operative assessment for the first data collection.  
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Some of the women who were thought to have ovarian cancer had benign disease after 
histological examination of the tissue.  A small number of women with no pathology were 
approached to measure baseline skin capillary density as part of validation of skin capillary 
measurements.   
 
2.2.  Inclusion criteria 
• All patients undergoing primary treatment with suspected or confirmed high 
grade serous ovarian cancer. 
2.3.  Exclusion criteria 
• Ovarian cancer patients with co-existing tumours 
• Patients who have received anti-angiogenic chemotherapy previously (e.g. 
bevacizumab) 
• Patients who have had radiotherapy, as the systemic effects of radiotherapy 
on angiogenesis are unknown 
 
2.4.  Data collection  
 
Patients who had 3b disease or less were offered primary surgery unless there was a clinical 
reason to offer neoadjuvant chemotherapy.  Those with more advanced disease or clinical 
contra indications for primary surgery underwent neoadjuvant chemotherapy.  Each patient 
was seen 5 times during their treatment as described in detail below. I recorded basal and 
maximal skin capillary density and collected serum samples at each visit.  At each visit I also 
recorded blood pressure and skin temperature.  Tissue was collected to make the diagnosis 
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(biopsy sample) and during major debulking surgery as part of routine care and details about 
preparation of tissue to count vessels is described in more detail below (section 2.9 page 66).  
 
There is a potential psychological impact and burden of taking part in a study in addition to a 
new diagnosis and treatment of cancer.  Additionally, for many women because of the 
intensity of the treatment, often feeling unwell and the arduous number of hospital visits, I 
did not ask women to attend on additional occasions for my data collection.  Instead, all tests 
were performed at the time of normal hospital attendance and I collected blood samples at 
the same time as chemotherapy-related investigations to avoid unnecessary repeat tests.  
The visit 48 hours post operatively was conducted on the ward.  In order to maintain 
consistency amongst patient visits, scrupulous organisation and follow up was required to 
ensure I did not miss data collection visits and that women were not required to attend more 
frequently.  This required a significant number of hours per week for me to monitor various 
hospital databases to keep a record of follow up clinics, potential complications from 
treatment, changes in treatment plans and outpatient and chemotherapy appointments.  
 
Patients reported enjoyment and enhancement in their care by taking part in the study and I 
was able to provide some continuity of care over the course of treatment and help to offer a 
greater understanding of their treatment pathway and access to information and support.  
On one occasion I was able to recognise a significant side effect of Bevacizumab treatment as 
the patient reported an episode of weakness during conversation.  I was able to organise 
urgent oncological review and the patient was diagnosed as having had a transient ischaemic 
attack.  I also took great enjoyment in seeing patients regularly and being able to follow up 
on clinical progress over the course of many months. 
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2.5.  Details of research visits 
 
Figure 2.1 summaries visits and treatment. 
2.5.1.  First visit: 
The first visit was scheduled prior to starting any treatment.  In some women who were having 
neoadjuvant chemotherapy, a diagnosis of high grade serous (HGS) ovarian cancer had been 
made by combination of histology or cytology and imaging.  The remaining women had 
suspected disease based on the aforementioned investigations.  In all cases women were seen 
prior to treatment.  Women were allowed to rest in a temperature-controlled room for 20 
minutes and blood pressure was measured.  Skin capillary density was measured as described 
later and 10ml of venous blood in a plain tube was collected alongside pre chemotherapy or 
pre-operative routine blood investigations.  The processing of blood samples is described 
below (section 2.8 page 62). 
 
2.5.2.  Second visit 
The second visit was scheduled either after 3 cycles of chemotherapy before interval 
debulking surgery or 48 hours after surgery in those women undergoing primary surgery.  
Bloods pressure, skin capillary density was measured and blood taken alongside pre-
operative bloods or routine post-operative bloods for those who were inpatients.  For those 
patients due to have surgery, information on mid treatment CT scan was recorded according 
to RECIST criteria.  RECIST criteria provides a standardised system to evaluate measurable 
lesions and response to treatment.  They are defined as the following: Complete response 
(CR): Disappearance of all target lesions.  Partial response (PR):  At least 30% decrease in the 
sum of the target lesions.  Stable disease (SD): Neither sufficient shrinkage to qualify PR nor 
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sufficient increase to qualify for PD.  Progressive disease (PD): At least a 20% increase in the 
sum of the larger lesions or the appearance of one or more new lesions.253  
 
2.5.3.  Third visit 
The third visit was scheduled for 48 hours or 2 weeks post operatively depending on the 
treatment pathway.  For those 2 weeks post-surgery, blood was collected from patients 
alongside pre chemotherapy bloods as a joint surgical and oncology appointment was usually 
scheduled for this time.  Skin capillary density and blood pressure was recorded in all patients.  
Information regarding surgery and surgical debulking outcome was also collected at this visit. 
 
2.5.4.  Fourth visit 
The fourth visit was scheduled for 2 weeks post-surgery or after 3 cycles of chemotherapy for 
those patients having primary surgery.  Blood pressure, skin capillary density and blood were 
measured in the same way as previously. 
 
2.5.5.  Fifth visit 
The fifth visit was scheduled for end of treatment for all patients.  Skin capillary density and 
blood pressure was recorded as well as outcome criteria of end of treatment CT scans.  This 
visit was conducted 4-6 weeks after completion of chemotherapy in correlation with routine 
follow up.  Blood was taken alongside routine bloods as part of end of treatment and baseline 
CA 125 measurements for those women embarking on routine follow up. 
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Figure 2.1.  Flow chart of visits and treatment. 
 
 
2.6.  Outcomes 
 
2.6.1.  Variables of interest  
 
Skin capillary density (number of vessels/mm2), CD 31 (number of vessels/field), PDGFR 
(number of vessels/field), VEGF (pg/ml), Ang 1 (pg/ml), Sol Endo (ng/ml): These was recorded 
in absolute values.  Change was calculated in absolute value change.   























Death and recurrent events were recorded.  Overall survival (OS) was calculated from time of 
diagnosis to time of death and was recorded in months.  Progression free survival was 
calculated from time of diagnosis to time of recurrence and was recorded in months. 
Surgical outcome was defined as optimal (complete or <1cm residual disease) or suboptimal 
(>1cm disease remaining). 
 
2.6.2.  Demographic details 
 
Patient demographics were gathered from clinical notes and clinic questionnaires to include 
clinical presentation, histology, initial computed tomographic (CT) findings, age, medical 
history, drug history, proposed chemotherapy.  All patients receiving chemotherapy for 
ovarian cancer had CT scans performed before, mid- and post-treatment. Data from the CT 
scans was recorded from the MDT reports during their follow up visits or from hospital data 
base systems and disease response characterised by the Response evaluation criteria in solid 
tumours (RECIST) criteria to Complete Response, Partial Response, Stable disease and 
Progressive Disease.253  
 
I collected this information in a database which was held securely on a gynaecological 
oncology folder, located on the Hospital server.  Anonymised data was backed up on another 
drive which was stored in a secure research office.  Data protection guidelines and 





2.6.3.  Definitions 
 
Surgical complications were also recorded and procedure scores were calculated depending 
on complexity of surgery.  Surgery included total abdominal hysterectomy, bilateral salpingo-
oophorectomy, appendicectomy, omentectomy, and excision of peritoneal disease.  
Extended procedures were those that included bowel resection, splenectomy, diaphragm 
resection and excision of lymph nodes.  Data from intra operative notes was collected and 
intra operative complications such as haemorrhage, visceral injury, blood transfusion and 
high dependency or intensive care admission.  Surgery was scored 0-3: 0 for standard surgery, 
1 for one additional extended procedure, 2 for two additional extended procedures and 3 for 
three additional extended procedures.   
 
2.6.4.  Subgroups 
 
Patients were categorised into groups for analysis according to the treatment they received.   
Neoadjuvant chemotherapy: These women had advanced disease at presentation so were 
treated with 3 cycles of chemotherapy followed by surgery and then 3 further cycles of 
chemotherapy. 
Primary surgery:  These women had debulking surgery followed by 6 cycles of chemotherapy. 
Neoadjuvant chemotherapy plus Bevacizumab:  These women had bevacizumab added to the 
3 cycles of chemotherapy after debulking surgery.  This was because of stage 4 disease or a 
suboptimal surgical outcome. 
ICON8b: These women were enrolled in an international trial and received neoadjuvant 
chemotherapy but had bevacizumab alongside chemotherapy from the start of treatment. 
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Chemotherapy only:  These women had neoadjuvant chemotherapy but did not undergo 
surgery after 3 cycles due to extensive disease or because they were medically unfit.  They 
continued with chemotherapy and received 6 cycles. 
 
2.7.  Methodology of Skin capillary density 
 
Capillaroscopy allows a 2D visualisation of a 3D capillary network in real time and software 
enables the images to be recorded as videos or stored as image files.   
Capillaroscopy was performed using a standardised validated method.237  Images and videos 
were obtained with a CapiScope camera and I analysed images using the computer software 
(KK Technology).   
 
Figure 2.2.  Set up of Capiscope and computer software 
 
A light sensitive black and white camera is mounted over a lens system and the skin is 
illuminated. A green filter enhances the contrast to improve images for analysis. The 
microscope can be moved over the patient skin on the standard mounting block.  Once over 
 58 
the correct point and perpendicular to the skin, it can be moved up and down to improve 
focus.  
 
Stringently controlled conditions for analysis are vital to ensure standardised and comparable 
examinations as capillary flow is susceptible to temperature, sympathetic drive and venous 
pressure.237  I therefore examined all patients in a temperature-controlled room of 21-24°C 
after 15-20 minutes of acclimatisation.  Patient were seated with hand at heart level during 
this period of acclimatisation.  I took this opportunity to discuss treatment plans and make 
notes of complications, CT scans and surgical information.  Skin temperature was also 
recorded.   
The middle finger of the left hand was used for each patient and four microscopic fields (1mm2 
each) around a central ink mark placed on the dorsum of the middle finger.  The finger was 
placed horizontally and immobilised between two plastic stabilisers to improve image quality.  
The microscope was focused on to the ink spot and a drop of oil placed on the ink spot in 







Figure 2.3.  Set up of finger immobilised for capillaroscopy.  Capiscope is seen mounted on a 
block which allows movement and focus to improve image quality. 
 
 
Images were recorded continuously for 5 minutes to permit detection of all perfused 
capillaries (basal skin capillary density) to provide functional skin capillary measurement.  In 
order to ascertain maximal capillary density, I recounted vessels after venous occlusion 
(paediatric sphygmomanometer cuff placed at base of finger and inflated to 60mmHg for 2 
minutes).  The number of capillaries were counted in one of the four microscopic fields chosen 
at random after the cuff inflation for 2 minutes.  The image during this point was focused at 




Figure 2.4.  Measurement of maximal (structural) skin capillary density with 
sphygmomanometer cuff placed at base of finger and inflated to 60mmHg for 2 minutes 
 
 
Initially I attempted to count the capillaries in live time however this took a considerable 
amount of time for the patient and so I chose to record the images and then analyse and 
count these off-line later the same day.  This also allowed me time to pause, rewind and 
recount areas to improve consistency and accuracy.  Recording videos also allowed for some 
to be recounted by me at a later date and by my supervisor to assess intra and interobserver 
variability of the technique.  20 videos were examined for intra and inter observer variability 
with 3% and 5% variability respectively.  This is consistent with the literature where 
reproducibility of capillaroscopy using these methods is reported at 5-8%.237 
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For each patient at each visit, the mean basal SCD was calculated as the mean count from the 
four microscopic fields.  Maximal SCD for then recorded for each patient at each visit.  Each 
video required around 30 minutes to count and calculate the mean. 
 
Figure 2.5.  Typical appearance of 1mm2 image of capillaries.  A: Basal SCD (functional).  B: 
Maximal SCD (structural).  Each black dot represents a capillary and is counted as part of 
calculating skin capillary density 












2.8.  Measurement of angiogenic factors 
 
2.8.1.  Collection and storage of serum 
 
I collected 10ml of blood in a plain Vacutainer tube at each visit.  As some patients had 
treatment at a hospital around 30 miles away I decided to leave samples to clot for 2 hours 
prior to centrifugation to allow time for me to return to the laboratory and process the 
sample.  They were then centrifuged at 3000g for 5 minutes.  After centrifugation serum was 
stored in 500 µl aliquots in Eppendorf tubes at -80°C.  Each study sample was given a number 
and I coded and recorded this in the laboratory book which was securely stored anonymously.  
All samples were stored and disposed of in accordance with the Human Tissue Act 2004. 
 
2.8.2.  ELISA technique 
 
Angiogenic factors were measured by enzyme-linked immunosorbent assays (ELISAs).  I used 
validated quantikine ELISA kits that had been described in the literature as I wanted the most 
reliable assay in view of the limited and essentially timed serum samples.  All of the ELISA 
techniques required smaller aliquots of 50-100 µl so in order to avoid repeat freeze-thaw 
cycles samples were split into smaller aliquots when ELISAs were carried out.  Each sample 
used for my analysis only underwent 1 freeze thaw cycle. 
 
All ELISAs employed the quantitative sandwich enzyme immunoassay technique.  In order to 
avoid cross contamination pipette tips were changed between additions of each standard 
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level, between sample and reagent additions.  All substrate solutions were protected from 
the light and an automatic pipette was used to help with accuracy. 
 
The r value of the standard curve was recorded for every plate reading and if >0.95 was 
thought to be acceptable.  The plate was repeated if the r value was too low.  Every sample 
was measured in duplicate and if the readings differed by more than 30% they were repeated.  
Raw data collected from the ELISA plates was processed using excel software into a 
concentration in the units of the standard. 
 
2.8.2.1. VEGF (DVE00 R&D systems) 
Instructions for reagent preparation and assay technique were followed according to the 
protocol.  All reagents and samples were bought to room temperature before use.  A 96 well 
plate was used which was pre coated with a monoclonal antibody specific for human VEGF.  
100 µl of assay diluent was added to each well.  100µl of the standard or sample were then 
added and incubated at room temperature for 2 hours.  A plate layout was used to recorded 
standards and samples assayed.  Each well was then aspirated and washed with wash buffer 
4 times, ensuring complete removal of any liquid at each wash and inverting the plate and 
blotting against paper towels.  200µl of the human VEGF Conjugate was added to each well 
and incubated for 2 hours at room temperature.  Wells were then aspirated and washed as 
previously described.  200µl of the substrate solution was added to each well and then 
incubated for 25 minutes at room temperature away from light.  50µl of the Stop Solution 
was added to each well and colour change from blue to yellow was observed.  A microplate 
reader set to 450nm was used to determine optical density within 30 minutes. 
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Figure 2.6.  Demonstration of the process of dilution of the standard. The stock solution is 
used to produce the dilution series.  500µl of calibrator diluent RD6U is pipetted into each 
tube.  Each tube is thoroughly mixed before the next transfer.  The 2000pg/ml standard serves 
as the high standard.  The calibrator diluent serves as the zero standard (0pg/ml). 
 
 
2.8.2.2. Angiopoeitin-1 (DANG10 R&D systems) and Soluble Endoglin (CD105 R&D systems) 
All reagents and samples were bought to room temperature before use.  A 96 well plate was 
used which was pre coated with a monoclonal antibody specific for human Angiopoietin- 1 or 
soluble endoglin.  The reagent and assay preparation was again prepared as per protocol and 









Table 2.1.  Description of procedure for ELISAs 






Soluble Endoglin  
(CD105 R&D systems) 
Assay diluent 100 µl 100 µl 100 µl 
Standard/Sample 100 µl 50 µl 50 µl 
First incubation 2 hours 2 hours 2 hours 
Wash buffer 4 times 4 times 4 times 
Conjugate 200 µl 200 µl 200 µl 
Second incubation 2 hours 2 hours 2 hours 
Substrate solution 200 µl 200 µl 200 µl 
Third incubation 25 minutes 30 minutes 30 minutes 
Stop solution 50 µl 50 µl 50 µl 
 
 
2.8.2.3. VEGF 165b (DY3045 R&D systems) 
There are limited validated ELISA kits for this protein, and I contacted various researchers 
across the country in order to gauge opinion on those that had produced reliable results.  
Unfortunately, many researchers had unsuccessful attempts at trying to measure VEGF 165b 
in an ELISA.  The ELISA that was used was also by R&D and had previously been developed at 
the University of Bristol and validated in other studies. 
 
Despite this it was difficult to measure.  Consistently producing an accurate standard curve 
with the kit used was not achievable despite a good technique and following the protocol.  
For some plates a curve was achieved but the levels were negative hence undetectable.  For 






2.9.  Tissue preparation and tumour vasculature and proliferative markers 
 
2.9.1.  Slide preparation 
 
Protein expression of the tumour vasculature and proliferation markers of interest were 
detected by antibodies using immunohistochemistry (IHC) staining techniques.   
Slides were prepared by a biomedical scientist.  At the time of biopsy and at primary or 
interval debulking surgery, tissue was removed and immersion fixed in formaldehyde and 
paraffin embedded (FFPE blocks).  Tissue blocks of areas representative of the invasive 
component of the cancer from metastatic tissue, either peritoneum or omentum were 
selected from the sections stained with haematoxylin and eosin by myself and an experienced 
Gynaecologic Consultant Pathologist.  The relevant 4-um tissue sections were cut from FFPE 
block using a microtome and mounted onto slides.  Slides were rehydrated and primary 
antibody detection was performed for Ki67, PDGFR and CD31 using validated protocols and 
detection kits from companies Abcam and R&D systems.  The figures below give examples of 









Figure 2.7A.  Paraffin embedded tissue stained with CD 31 antibody.  2.7B Paraffin embedded 
tissue stained with Ki67 antibody.  Brown staining represents a blood vessel in the case of CD 
31 antibody or nuclei staining for ki67. 





2.9.2.  Calculation of vascular and proliferative markers 
Ki67 was calculated as a percentage of nuclei stained.  This was done independently by myself 
and a specialised Gynaecologic Consultant Pathologist to improve accuracy and reliability. 
Microvessel density using CD31 and PDGFR was calculated using the validated Weidner 
method.187  We selected areas with the highest density of microvessel (hotspots) at low 
magnification.  All the vessels in the region were then manually counted in these areas at high 
magnification (200x-400x).  Any brown or blue staining endothelial cell or cluster that was 
seen separately from tumour cells and other connective tissue element was considered a 
single vessel.  Vessels were counted by myself and the Pathologist on double headed light 
microscopes concurrently to ensure agreement and consistency.  Each count took around 10 




2.9.3.  Chemotherapy response score 
Chemotherapy response score (CRS) was calculated for each specimen taken at interval 
debulking surgery by an experienced tertiary specialist Pathologist in Gynaeoncology.  CRS is 
a simple and reproducible grading system to assess response to neoadjuvant 
chemotherapy.254  The International Collaboration on Cancer Reporting (ICCR) has 
recommended clear guidance on the assessment of CRS which involves assessment of a single 
block of omental tissue that shows the least response to chemotherapy.255  The amount of 
viable tumour is assessed and graded on a three tier system; >95% of tumour should be viable 
for a score of 1 and <5% for a score of 3.255  Table 2.2 is taken from the ICCR to describe the 
difference scoring mechanisms for CRS. 
 
Table 2.2.  Characteristics for chemotherapy response scoring: recommendations from the 
International Collaboration of Cancer Reporting (ICCR)255 
Score Criterion Tumour regression grading 
1 Mainly viable tumour with minimal regression-
associated fibro-inflammatory changes limited to 
a few foci 
No or minimal tumour 
response 
2 Multifocal or diffuse regression-associated fibro-
inflammatory changes, with viable tumour 
ranging from diffuse sheets, streaks or nodules, 
to extensive regression with multifocal but easily 
identifiable residual tumour 
Partial tumour response 
 
3 Mainly regression, with few irregularly scattered 
individual tumour cells or cell groups (all 
measuring <2 mm), or no residual tumour 
identified 







2.10.  Statistical considerations  
 
I received guidance from a University of Bristol statistician, Dr Sofia Kavanou, throughout my 
analyses to improve my understanding of methods and ensure that I processed my data 
correctly.   
 
In order to ensure enough participants were recruited to detect a correlation between 
variables we used R software package to perform the calculation.  A cohort of 50 patients 
with full data on 90% (45) of the participants would give 88% power to detect correlations as 
low as 0.45 as statistically significant at the 5% level between capillary density or VEGF and 
PFS, OS.  This would be sufficient to provide proof of concept required to take this study 
further and use the data to inform plans for subsequent studies.  
 
Repeated measures ANOVA revealed non-linear trends in longitudinal analysis.  To adjust for 
the heterogeneity present between treatment groups, a mixed model with unstructured 
covariance was fit. For pairwise comparisons we used Tukey’s HSD post-hoc adjustment to 
account for Type-I error inflation. 
 
I have detailed descriptive statistics for demographics and clinical characteristics for the 
entire cohort and specifically for those studied in each chapter.  Continuous variables were 
reported as mean and standard deviation.   
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Continuous variables were dichotomised to above and below means when compared with 
outcomes in logistic regression and Kaplain Meier models.  ROC curves were constructed to 
predict optimal cut off points. 
 
Associations between continuous variables were analysed with linear regression models.  
Logistic regression models were used to determine associations between continuous 
variables and outcomes. Comparison of means was assessed with non-parametric t tests 
(Mann Whitney) and categorical variables used Spearman’s Rank and Kendall tau test.  
ANOVA was used to compare differences between groups.  Kaplain Meier analysis was used 
to estimate the survival outcomes and construct progression free survival (PFS) and overall 
survival (OS) curves.  To assess the prognostic value of variables to OS and PFS curves were 
compared using the log rank test.  Univariate and multivariate cox proportional hazards 
modelling was used to test associations between variables and outcomes.  Where appropriate 
models were adjusted for age, performance status, stage of disease, treatment and surgical 
outcomes.  Statistical significance was defined as p<0.05.   
 
I used IBM SPSS Statistics version 25, PRISM 8 and Microsoft® Excel for Mac to perform the 
analyses. 
 
2.11.  Ethics 
 
The study was granted ethical approval  on 15th February 2016 by REC Nottingham Research 
Committee (ref: 15/EM/0489) and was sponsored by Universities Hospital Bristol.  Consent 
processes were consistent with GMC guidance on ‘Good Medical Practice in Research’.  
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Participants confidentiality was maintained throughout the study and all documents were 
stored securely and only accessible by myself.  These were kept in a Site file secured on 
premises.  The study complied with the Data Protection Act and Human Tissue Act and all 
data was anonymised.   
 
2.12.  Funding 
 
I achieved funding from David Telling Trust for £11,309 to buy the capillary microscopy and 
£14, 440 from Above and Beyond to fund analysis of serum and tissue samples.  Insurance 
















Chapter 3.  Validation of skin capillary density 
 
3.1.  Introduction 
 
Absolute values for skin capillary density in the healthy population are heterogenous.  Values 
in the literature range from 40 to 85 (vessels/mm2).239, 240, 242-246, 248, 256 when SCD has been 
investigated in health and in the presence of cardiovascular disease, hypertension, diabetes, 
rheumatological disease and pregnancy.  However there is not a specific range or value that 
denotes health or disease265.  Skin capillary density has been shown to decrease in patients 
with hypertensive disease compared to normotensive patients or those with well controlled 
and treated hypertension.237, 242 
 
In order to ensure my methods of measuring skin capillary density were reliable I carried out 
measurements in healthy patients and those with benign disease to help validate my 
methodology prior to recruitment of my study cohort. 
 
3.2.  Methods 
 
I measured mean basal and maximal SCD in 10 healthy age matched volunteers.  I also 
measured SCD in 2 subjects at 3 points throughout the day in order to assess the time on 
possible variations in SCD measurements.  10 women who were undergoing primary surgery 
for an ovarian mass with low risk of malignancy were also included.  All these women had 
benign disease confirmed on histological examination.  Differences in mean skin capillary 
density were compared using Wilcoxon test 
 73 
3.3.  Aims. 
• To validate methodology of capillaroscopy 
 
3.4.  Results 
 
3.4.1.  Demographics of cohort 
The mean age and BMI of patients amongst all groups were comparable.  No patients had 
uncontrolled hypertension or history of rheumatological disease which may have affected 
SCD values.  Table 3.1 describes the demographics in the groups. 
 
Table 3.1.  Skin capillary density (vessels/mm2) and demographics of all patients  









69.8 (11.2) 69.0 (4.4) 67.0 (5.6) 0.53 
BMI (kg/m2) 
Mean (SD) 
25.6 (4.7) 28.0 (4.1) 27.5 (5.7) 0.33 
 
3.4.2.  Skin capillary density variation throughout the day  
Skin capillary density was measured in 2 healthy controls on 3 occasions 15 minutes apart at 
9am, 12pm and 3pm.  Mean basal SCD did not vary significantly throughout the day (p=0.60) 
and this was the case for both control patients.  Similarly maximal SCD values remained stable 
at both 9am, 12pm and 3pm (p=0.40).  Table 3.2 records the values of skin capillary density 
at different time points throughout the day.   
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Table 3.2.  Variation in skin capillary density (vessels/mm2) during the day 
Mean basal 9am 12pm 3pm P value 
Control 1  58, 59 60, 60 56, 61 0.600 
Control 2 63, 66 60, 61 66, 60 0.400 
Maximal      
Control 1 61, 69 70, 67 70, 71 0.733 
Control 2 70, 71 69, 67 71, 69 0.467 
 
 
3.4.3.  Differences in skin capillary density in malignant, benign and control group 
I compared the baseline values of those women recruited in the study with malignant disease, 
with those who had benign disease and the control cohort.  Mean basal SCD at baseline varied 
between the groups and was 62.9, 57.6 and 65.2 vessels/mm2 in the benign, control and 
malignant cohort respectively (p=0.018).  Variation between the groups for maximal SCD was 
not significant (p= 0.258) and was 68.2, 66.0 and 70.2 vessels/mm2 for the benign, control 
and malignant cohort. 









Figure 3.1.  Box plot of mean basal SCD (vessels/mm2) at baseline for the different groups 






When those with benign disease were compared with patients who had malignancy there 
was no significant difference in SCD in either mean basal or maximal SCD values (62.9 vs 65.2 
vessels/mm2 p=0.313 and 68.2 vs 70.2 vessels/mm2 p= 0.411 respectively). 
 
There was a significant difference between the control group and those who had malignancy 
in regards to mean basal SCD (65.2 vs 57.6 vessels/mm2 p=0.0061) but this was not seen in 
maximal SCD values (70.2 vs 66.0 vessels/mm2 p=0.124). 
  
The difference between SCD in the control and benign group was not significantly different 
for mean basal or maximal values (57.6 vs 62.9 vessels/mm2 p=0.062  and 66.0 vs 68.2 
vessels/mm2 p =0.638 respectively). 
 
Table 3.3 records mean basal and maximal skin capillary density (vessels/mm2) in patients in 
the control and malignant disease cohorts. 
 
Table 3.3.  Skin capillary density (vessels/mm2) in control and malignant cohort of patients 





Mean basal SCD 57. 6 (4.3) 65.2 (9.4) 0.0061 






3.5.  Discussion 
 
Skin capillary density did not appear to vary throughout the day which suggests that 
measuring at a consistent time point (early morning) as was done with my study cohort is 
reliable.  This is also alongside ensuring the appropriate measures were taken as described in 
the main methods section in order to standardise the technique. 
 
There is no data for skin capillary density in ovarian cancer to date.  Furthermore it has not 
be studied as a marker to determine cancer from benign ovarian lesions or healthy controls.  
In this cohort of patients mean basal skin capillary density was significantly higher in the 
malignant group compared to healthy controls whereas there was no significant difference in 
maximal capillary density.  This suggests that structural capillary density is unchanged but 
perfusion of those capillaries may be altered in the presence of malignancy.  A limitation is 
that the number of controls in this cohort was smaller than that in the malignant group and 
further work is necessary on a larger scale if conclusions are to be drawn regarding the value 
of SCD in predicting malignancy. 
 
3.6.  Conclusion 
 
The aim of this work was to ensure my methods of measuring skin capillary density were 
reliable and those values I obtained in the benign and control group are in keeping with the 
ranges published in the literature.  The paucity of data of SCD in ovarian cancer makes it 
hard to be confident of a ‘normal range’ but I feel assured that my technique is validated 
and my methods are robust and reliable.  
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Angiogenesis is a key component of cancer growth and metastasis.66  The development and 
maintenance of capillaries is also dependent on angiogenesis.  VEGF is a potent promotor of 
angiogenesis and chronic VEGF inhibition leads to capillary regression in animal models.257  
Ang 1 stabilises new vessels and acts synergistically with VEGF to promote tumour 
angiogenesis.133, 134   Endoglin is expressed on proliferating endothelial cells that undergo 
neovascularisation and form disorganised leaky vessels, those classic of tumour vessels.258  A 
soluble form (soluble endoglin) has been shown to be raised in colorectal and breast cancer 
and has not been studied longitudinally in ovarian cancer treatment before.  It is also 
implicated in vascular resistance and been demonstrated to induce hypertension in vitro due 
to its effect on endothelial cell function.142  It would be interesting to see whether higher 
soluble endoglin levels are associated with capillary rarefaction.  
 
Skin capillary density is a dynamic variable and has been studied widely in the context of 
vascular disorders such as cardiovascular disease, hypertension and ageing.  Insufficient 
angiogenesis has been suggested as a possible mechanism for capillary rarefaction249 however 
associations between angiogenic markers such as VEGF and capillary density have yet to be 




Treatment for ovarian cancer consists of chemotherapy and surgery although therapies are 
beginning to become personalised alongside the introduction of genetic testing in patients.  
Anti angiogenic drugs are being developed and used in conjunction with standard treatments 
such as chemotherapy where they have demonstrated an increased in PFS35, 153, 155 however 
these are not yet widely used or funded for all patients with ovarian cancer in both the first 
line and recurrence setting.   
 
Personalised medicine requires targeted therapies to achieve the best outcome for an 
individual.  Identifying patterns of disease and clinical responses to treatment can help to 
determine the most effective interventions for an individual. 
 
Skin capillary density and angiogenic markers are dynamic variables that may be helpful in 
identifying patients who are responding to treatment in ovarian cancer or who may benefit 
from additional therapies, particularly anti angiogenic drugs.  In order to investigate this 
hypothesis, skin capillary density and angiogenic markers were studied longitudinally 




• To identify changes in skin capillary density throughout treatment in ovarian cancer 
• To identify changes in angiogenic factors throughout treatment in ovarian cancer 






Participants were recruited as described in the Methods section (section 2.1 page 49).  
Written informed consent was obtained from each participant.    Mean basal and maximal 
skin capillary density were recorded at each visit along with angiogenic markers.  Every 
subject had a visit before starting treatment known as the baseline visit.  Measurements were 
then taken after 3 cycles of chemotherapy, 48 hours and 2 weeks post operatively in those 
who underwent surgery and finally at the end of treatment.   
 
I initially analysed all treatment groups up to the first five visits as these included the 
treatment duration for all groups, visit 5 being at the end of standard treatment.  Those in 
ICON8b or those who were given Bevacizumab post operatively continued on maintenance 
therapy after this time.  I conducted pair wise comparisons of maximal and basal capillary 
density and angiogenic markers between each visit and in comparison to baseline. 
 
Those women who had chemotherapy only and no surgery were followed up for 3 visits.  
Those who had chemotherapy and surgery with or without the addition of Bevacizumab were 
followed up for 5 or more visits.  Those who were on maintenance Bevacizumab  either post 
surgery or from the start of treatment (ICON8b) were followed up an additional 2 visits in 






Table 4.1.  Summary of observations at each visit according to treatment 
*No patients were lost to follow up.  Missing values were due to death of the patient. 
  
4.3.1.  Statistical analysis 
 
Univariate and multivariate analysis was performed to predict the effect of variables on 
overall survival and progression free survival.  OS was defined as time from diagnosis to death 
and PFS from diagnosis to first recurrence.  Both were reported in months. 
In regard to longitudinal analysis, I focused on the comparison of neoadjuvant chemo, 
neoadjuvant chemo plus Bevacizumab and ICON 8b patients to visit 5 as these three groups 
were the most comparable at visit time points.   
The longitudinal changes in capillary density and angiogenic markers were analysed using 
repeated measures ANOVA which revealed non-linear trends in the treatment groups.  To 
adjust for the heterogeneity present between the groups, a mixed model with unstructured 
covariance was fit.  For pairwise comparisons Tukey’s HSD post-hoc adjustment was used to 
Treatment Time (visit) Total 
1 2 3 4 5 6 7 
Chemotherapy only 10 7 7 0 0 0 0 24 
Icon8b 6 6 6 6 5 4 4 37 
Neoadj. chemotherapy 20 20 20 19 16 11 6 112 
Neoadj. chemotherapy + 
bevacizumab 
9 9 9 9 9 8 5 58 
Primary surgery 5 5 5 5 5 0 0 25 
Total 50 47 47 39 35 23 15 256 
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account for Type-I error inflation.  Statistical significance was declared when the p value was 
<0.05. 
 
Women having primary surgery were analysed separately by repeated ANOVA and those who 
received only chemotherapy were also not included in the model and were also analysed 
separately.  This was because their number of visits were less and I felt that the model was 
too heterogenous to include this later two treatment groups due to where in time they 






All 50 (100%) women had high grade serous disease at histological examination of the 
tumour.  Stage ranged from 2b to 4 disease.  All 45 (90%) of those who had neoadjuvant 
treatment prior to surgery had stage 3 or 4 disease.  All 5 (10%) of those with stage 2 disease 
radiologically underwent primary surgery.   
 
In regard to treatment, 20 (40%) women had neoadjuvant chemotherapy.  The treatment 
consisted of 3 cycles of chemotherapy followed by a mid-treatment CT.  This CT was reported 
according to RECIST criteria which is further described in the main methods section (section 
2.5.2 page 52).  Those with a partial response to chemotherapy and suitable fitness 
underwent debulking surgery followed by 3 more cycles of chemotherapy.  An additional 
subgroup of 9 (18%) women had Bevacizumab treatment added to the 4th and 5th cycles of 
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chemotherapy.  This was either because of stage 4 disease or suboptimal surgical debulking 
outcome.  6 (12%) women in the study were enrolled into the ICON8b trial which involved 
having Bevacizumab in addition to chemotherapy in cycles 1, 2, 5 and 6.  This trial is described 
in detail in the main methods section.  10 (20%) patients had chemotherapy only, either 
because they were not fit for surgery or had too extensive disease thought suitable for 
resection by the multidisciplinary team.  The remaining 5 (10%) patients had primary 
debulking surgery followed by 6 consecutive cycles of chemotherapy. 
 
Table 4.1 A and B describes the demographics in all patients.  There were no significant 
















Table 4.1 A Demographics of all patients 
 N= 50 
Characteristic  
Age at diagnosis (years) 69.5 (10.8) 
<65 16 (32%) 
65-70 8 (16%) 
>70 26 (52%) 
BMI (kg/m2) 26.1 (4.76) 
History of hypertension (yes) 4 (9.5%) 
Ca-125 553 (69, 40000) 
Performance status at diagnosis  
0 10 (20%) 
1 32 (64%) 
2 8 (16%) 
Tumour stage  
2b 5 (10%) 
3b 7(14%) 
3c 22 (44%) 
4 16 (32%) 
Treatment  
Primary surgery 5 (10%) 
Neoadjuvant chemotherapy 39 (78%) 
Chemotherapy only 10 (20%) 
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Neoadjuvant chemotherapy (Bev post treatment) 9 (18%) 
Icon8b 6 (12%) 
Type of surgery   
Complete/optimal 33 (66%) 
Suboptimal 8 (16%) 
Unfit/died/inoperable 9 (18%) 
Chemotherapy response score  
1 11 (26%) 
2 18 (48%) 
3 7 (17%) 
Bevacizumab treatment (Yes) 15 (36%) 
Death (Yes) 20 (48%) 













Table 4.1B.  Characteristics of patients according to treatment pathways 




























24.9 (5.3) 27.4 (4.9) 26.5 (4.3) 25.1 (2.7) 
 
29.8 (4.9) 0.254 
CA 125 Mean (SD) 1320 (1448) 6552 (12948.2) 918 (1471.7) 853 (959.2) 284 (238.5) 0.136 
 




























































































































4.4.2.  Survival analysis  
 
Median overall survival was 21 months.  Median progression free survival was 19 months. 
Univariate analysis was carried out to see the impact of various variables on overall survival 
(table 4.2).  When comparing treatments, those women who had chemotherapy only with no 
surgery had a significant worse overall survival.  The outcome of surgery had a significant 
impact on overall survival (HR 0.231 (0.099-0.537) p= <0.001).  Patients who had optimal 
surgery had a 76.9% reduction in risk of death compared to those with suboptimal outcome.  
Patients were excluded if they were unfit for surgery.   
 
Performance status also impacted on survival and those women with a performance status 
of 2 were estimated to have a higher risk of death compared to those with status 1 or 0 (HR 







Table 4.2. Summary of univariate Cox models for Overall survival  
Number of patients: 50 
Number of events: 23 
   
 Characteristics  Hazard ratio 95% CI p-value 
Treatment  
(Primary surgery group omitted) 
   
Neoadjuvant chemo vs Chemo only 0.211 (0.079, 0.0562) 0.0019 
Neoadjuvant chemo with 
Bevacizumab  vs Chemo only 
0.208 (0.062, 0.692) 0.0105 
Icon8b vs Chemo only 0.154 (0.032, 0.730) 0.0185 
Addition of Bevacizumab in 
chemotherapy 
   
No addition vs post-op 1.580 (0.619, 4.037) 0.339 
Surgery outcome    
Optimal vs suboptimal 0.231  (0.099, 0.537) <0.001 
Age at diagnosis 1.021  (0.980, 1.064) 0.324 
Performance status at diagnosis    
0 vs 2 0.050  (0.006, 0.418) 0.006 
1 vs 2 0.008  (0.113, 0.713) 0.009 
Chemotherapy Response Score 
(CRS)* 
   
Good vs Poor 0.281 (0.088, 0.895) 0.032 
Cancer stage     
Stage-IV vs Stage-III 2.072 (0.911, 4.709) 0.082 
*CRS 1:poor CRS 2/3: good. 
 
 89 
Univariate analysis was also carried out for progression free survival (Table 4.3).  It showed 
that treatment appeared to have a less significant impact on PFS compared to OS.  However 
patients who had optimal surgery had a 58.3% reduction in risk of recurrence compared to 
those with suboptimal surgery (HR 0.417 (CI 0.210, 0.828) p= 0.012).  A good chemotherapy 
response score (CRS) score of 3 was estimated to be a less hazard of recurrence by 92.4% 





















Table 4.3. Summary of univariate cox models for Progression free survival  
Number of patients: 50 
Number of PFS events: 35 
   
Characteristics Hazard ratio 95% CI p-value 
Treatment  
(Primary surgery group omitted) 
   
Neoadjuvant chemo & surgery vs 
Chemo only 
0.914 (0.375, 2.227) 0.130 
Neoadjuvant chemo with 
Bevacizumab & surgery vs Chemo only 
1.157 (0.429, 3.124) 0.773 
Icon8b vs Chemo only 0.348 (0.089, 1.364) 0.130 
Addition of Bevacizumab in 
chemotherapy 
   
No addition vs post-op 1.036 (0.510, 2.103) 0.923 
Surgery outcome     
Optimal vs suboptimal 0.417  (0.210, 0.828) 0.012 
Age at diagnosis 1.005  (0.975, 1.037) 0.736 
Performance status    
0 vs 2 0.380  (0.115, 1.254) 0.112 
1 vs 2 0.531  (0.211, 1.335) 0.178 
Chemotherapy Response Score (CRS)*    
Good vs Poor 0.039  (0.005, 0.314) 0.002 
Cancer stage     
Stage-IV vs Stage-III 1.478  (0.750, 2.915) 0.259 
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*CRS 1:poor CRS 2/3: good. 
 
Multivariate analysis was performed and model was adjusted for age, performance status, 
stage and surgical outcome.  Those who received chemotherapy only had an increased risk of 
recurrence compared to those who had debulking surgery with or without Bevacizumab (HR 
7.98 (CI 1.085-58.75) p=0.041).  Optimal debulking and good chemotherapy response score 
remaining positive factors for improved OS and PFS. (Table 4.4, 4.5). 
 
Table 4.4. Summary of multivariate cox models for progression free survival  
Number of patients: 50 
Number of PFS events: 35 
   
Characteristics Hazard ratio 95% CI p-value 
Treatment  
(Primary surgery group omitted) 
   
Chemo only vs Neoadjuvant chemo 2.318 (0.578, 9.290) 0.235 
Chemo only vs Neoadjuvant chemo 
with Bevacizumab 
7.984 (1.085, 58.750) 0.041 
Icon8b vs Chemo only 0.665 (0.108, 4.077) 0.659 
Surgery outcome     
Optimal vs suboptimal 0.242 (0.061, 0.969) 0.045 
Chemotherapy Response Score (CRS)    
Good vs Poor 0.121 (0.017, 0.838) 0.032 





Table 4.5 Summary of multivariate cox models for overall survival  
Number of patients: 50 
Number of PFS events: 35 
   
Characteristics Hazard ratio 95% CI p-value 
Treatment  
(Primary surgery group omitted) 
   
Chemo only vs Neoadjuvant chemo 2.713 (0.418, 17.593) 0.295 
Chemo only vs Neoadjuvant chemo 
with Bevacizumab 
3.072 (0.315, 30.009) 0.334 
Chemo only vs ICON 8b 2.968 (0.352, 24.993) 0.317 
Surgery outcome     
Optimal vs suboptimal 0.169 (0.026, 1.107) 0.064 
Chemotherapy Response Score (CRS)    
Good vs Poor 0.538 (0.140, 2.068) 0.367 
*CRS 1:poor CRS 2/3: good. 
 
4.4.3.  Longitudinal analysis 
 
A total of 256 measurements were analysed across all treatment groups (table 4.6).  Skin 
capillary density was recorded at every visit.  Blood was also taken at every visit however 
during ELISA experiments and data analysis, some unreliable values for VEGF were obtained 
which I considered inaccurate and therefore omitted.  This led to a 51 VEGF values being lost 




Table 4.6. Summary of observations per time point 
Time (Visit) Frequency Percent Cumulative Cumulative 
Frequency Percent 
1 50 19.53 50 19.53 
2 47 18.36 97 37.89 
3 47 18.36 144 56.25 
4 39 15.23 183 71.48 
5 35 13.67 218 85.15 
6 23 8.98 241 94.13 
7 15 5.87 256 100.00 
 
Table 4.7 summarises the effect of time and treatment on the various factors of interest.   
Both VEGF and Ang 1 decreased over the 5 visits in all treatment groups and maximal and 
mean capillary density also decreased over time.  There was no difference in soluble endoglin 
over the course of treatment.   The model was adjusted for treatment and there was no effect 
of treatment on the changes observed.  
 








Treatment 0.922 0.019 0.2289 0.1089 0.2437 
Time 0.022 <0.001 0.6330 <.0001 <.0001 




4.4.3.1 Skin capillary density 
 
Figure 4.1 demonstrates the individual profile plots of changes in skin capillary density 
(vessels/mm2) from start to end of treatment for all patients.   
 
Figure 4.1.  Change in SCD for all individual patients.  Each line represents an individual 
patients SCD from the start and end of treatment. 
 
The mean basal skin capillary density had a gradual decline during treatment in all groups.   
Mean basal skin capillary density fell significantly at each visit compared to baseline (Table 
4.7).  The most significant drop was from baseline to the visit immediately after surgery.  
Although it then increased it never returned to baseline.  Overall the trend in mean changes 





Table 4.8. Pairwise comparisons of mean basal SCD (vessels/mm2)measurements over time 
 
Visit 1 2 3 4 5 












































Figure 4.2.  Model adjusting for treatment demonstrating changes in mean basal SCD 





Similarly mean maximal capillary density significantly fell at each visit compared to baseline 
(Table 4.8)  The most significant drop was from baseline to visit 3 immediately after surgery.  
Overall the trend in mean changes in maximal skin capillary density from baseline were 
statistically significant (p=<0.0001) (Figure 4.3).   
 
 
p value = <0.0001 
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Table 4.9. Pairwise comparisons of mean maximal SCD (vessels/mm2) measurements over 
time  
 
Visit 1 2 3 4 5 










































Figure 4.3.  Model adjusting for treatment demonstrating changes in mean maximal SCD 




The effect of treatment on mean basal SCD over time was significant for all 3 groups (Icon8b 
p-value=0.004; neoadjuvant chemotherapy p-value =0.001; neoadjuvant chemotherapy plus 
Bevacizumab p-value= 0.018) , after comparison of measurements recorded during the first 





p value = <0.0001 
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4.4.3.2 Angiogenic markers 
 
Figure 4.4 (a, b, c) below demonstrates the individual profile plots of changes in angiogenic 
markers from start to end of treatment for all patients.   
 
Figure 4.4.  Markers in all patients from start to end of treatment.  4.4a VEGF.  4.4b Ang 1.  











4.4b Ang 1 
 




The levels of mean VEGF reduced at each visit compared to baseline.  The largest and most 
significant decline in VEGF occurred from baseline to 2 weeks following surgery (visit 4, 
p=0.04) (Table 4.9)  
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There was no difference in the change of VEGF according to treatment and whether women 
received Bevacizumab. 
Overall there was a decline in VEGF throughout treatment and this was statistically significant 
(p=0.02) (figure 4.5).  
 
Table 4.10. Pairwise comparisons of mean VEGF measurements over time using Tukey’s HSD.  
 
Visit 1 2 3 4 5 











































4.4.3.2.2 Ang 1 
The levels of mean Ang 1 reduced at each visit compared to baseline.  The largest and most 
significant decline in Ang 1 occurred at the start of treatment from baseline to visit 2 
(p=0.0002) (Table 4.10). 
There was no difference in the change of Ang 1 according to treatment and whether women 
received Bevacizumab. 
Overall there was a decline in Ang1 throughout treatment and this was statistically significant 
(p=<0.001) (figure 4.6).   
p value = 0.02 
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Table 4.11. Pairwise comparison of mean Ang1 measurements over time.  
 
Visit 1 2 3 4 5 

























































p value = <0.001 
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4.4.3.2.3. Soluble endoglin 
There was no significant differences in the levels of soluble endoglin during treatment 
(p=0.63). 
 




4.4.3.3. Chemotherapy only 
Table 4.11 below demonstrates the fall in factors in the chemotherapy only group.  There was 
a significant drop in baseline to visit 2 and from baseline to visit 3 for mean basal and maximal 
SCD (p=<0.001).  A significant drop in VEGF and Ang 1 was also seen from baseline to visit 2 
and 3 (p=<0.001) 
p value = 0.63 
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Table 4.12.  Pairwise comparison of mean markers over time for patients receiving 
chemotherapy only 
 Visit Visit Difference 
Mean (SD) 
P value 
Mean basal SCD 1 2 -6.79 (1.56) 0.0005 
 1 3 -12.3 (2.27) <0.001 
 2 3 -5.49 (2.50) 0.141 
Maximal basal SCD 1 2 -6.2 (1.30) 0.0001 
 1 3 -10.28 (1.94) <0.0001 
 2 3 -4.06 (2.06) 0.216 
VEGF 1 2 -623 (131) <0.001 
 1 3 -102.9 (194) <0.001 
 2 3 4.06 (2.07) 0.056 
Ang 1 1 2 -22277 (4251.8) <0.0001 
 1 3 -21821 (3832.3) 0.0001 












This the first study investigating skin capillary density in ovarian cancer.  It is also the first 
study where angiogenic markers have been measured at time points throughout treatment. 
I discovered that capillary rarefaction occurred in all women irrespective of nature and 
duration of treatment (p= <0.001).  Furthermore, there is a significant reduction between 
baseline and visit one which was measured after 3 cycles of chemotherapy with or without 
Bevacizumab.  A further significant drop is also demonstrated between visit 2 and 3 which 
was measured after surgery.  The levels then increase but never return to baseline.  This is 
demonstrated in both mean and maximal skin capillary density suggesting not only a 
functional drop in skin capillaries but also a structural reduction in the number of vessels. 
Capillary rarefaction during cancer treatment has not been demonstrated before and I 
postulate that this may be a reflection of a fall in angiogenic activity.  This would correspond 
with a fall in the angiogenic markers of VEGF and Ang 1 which I have also demonstrated.   
 
There was a fall of VEGF between baseline and visit 1 and then a small rise after surgery but 
overall there was a downwards trend across the treatment phases.  The levels of Ang 1 
significantly fell from baseline to visit 1 and that drop was maintained throughout the rest of 
the treatment.  I did not demonstrate any change in soluble endoglin during treatment. 
 
It has previously been documented that serum VEGF increases after major abdominal surgery 
in patients with colorectal cancer259  as well as similar reports seen in breast cancer surgery.260    
As VEGF is a potent promotor of angiogenesis it is reasonable to expect an increase after 
surgery to promote healing and recovery.  However, in this cohort of patients, although 
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immediately after surgery VEGF rises, it then continues to fall again towards end of treatment 
with an overall trend of reduction from baseline to end of treatment.   
 
Tumour derived VEGF enhances tumour spread, dissemination and high levels of VEGF at 
diagnosis both in serum and tissue are widely known to correspond to more advanced disease 
and poor outcomes in ovarian cancer.87, 97-103  It is logical that reduction in tumour bulk by the 
end of treatment would mirror reduction in serum VEGF measurements and serum VEGF 
levels have been shown to reduce after resection of other tumours and completion of 
chemotherapy.261, 262  This is the first study to demonstrate this dynamic change in ovarian 
cancer.   
 
Ang 1 is another potent stimulator of angiogenesis and has been demonstrated to have a 
synergistic effect with VEGF.138  In ovarian cancer higher levels of Ang 1 are demonstrated in 
malignant tumours compared to benign controls and associated with worse overall and 
progression free survival.139  In those patients on Bevacizumab, high Ang 1 levels at baseline 
did predict an improved PFS in a small group of patients.140  Although this data has not be 
validated in larger studies, it can be postulated that in those patients with a higher angiogenic 
drive at baseline may respond best to anti angiogenic inhibitors.    
 
In my cohort of patients, serum levels of Ang 1 fell in all treatment groups particularly at the 
start of treatment.  While there was no significant difference in those who had Bevacizumab, 
my finding of an effect of treatment on levels is promising.   
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It must be considered whether the fall in skin capillary density and angiogenic markers in all 
patients is a consequence of a change in measuring technique over time.  However I think this 
is unlikely as the patients entered and went through the study at different times and care was 
taken to ensure collection of data was standardised and consistent.  The universal feature is 
that all patients received chemotherapy.  Cytotoxic treatment leads to vascular dysfunction 
and may have a direct impact on angiogenesis263 and this may be reflected in the  reduction 
in skin capillary density and angiogenic markers in these patients. 
 
Demonstration of an effect of an intervention on a marker is a key part of development of a 
biomarker in clinical medicine.  I have demonstrated that skin capillary density appears to 
alter after treatment in women with ovarian cancer.  It is important not only validate these 
results with a larger number of women but also ascertain this change in relation to outcomes 
such as surgical resection, overall survival and recurrence.   
 
4.6.  Conclusion 
This is the first study to my knowledge that has demonstrated a reduction in angiogenic 
markers during treatment for ovarian cancer.  Skin capillary density also significantly fell 
during treatment.  There is a paucity of data in the literature regarding skin capillary density 
amongst cancer patients and my data suggest a promising dynamic change that has potential 






Chapter 5: Skin capillary density and cancer outcomes 
 
5.1  Introduction 
 
In my previous chapter I demonstrated that skin capillary rarefaction (fall in skin capillary 
density) occurred during treatment for ovarian cancer.  Capillary rarefaction has not been 
studied thus far in ovarian cancer and my research contributes this novel finding.  However, 
the implication of these changes must be assessed in order to determine their value. 
 
It is well recognised that most women present with advanced stage disease (stage 3 or 4) and 
only a third of these women survive beyond 3 years.1-4   Additionally, recurrence occurs in the 
vast majority of women.45  Advanced stage of disease and response to platinum-based 
chemotherapy are factors that impact on overall survival and recurrence.  Surgical outcome 
also has a significant impact on overall survival for women with ovarian cancer and residual 
tumour after surgery is an independent prognostic factor for recurrence and survival.42-46 
The Gynaecological Oncologic Group (GOG) trials demonstrated that those patients with no 
residual disease had improved overall survival (OS) compared to those with <1cm residual 
disease (64 months vs 29 months).44  
 
Additionally, a Cochrane review demonstrated that maximal surgical effort is a key 
determinant of survival outcome with the goal of achieving complete cytoreduction.43  Those 
women with >1cm macroscopic disease remaining had an increased risk of death compared 
to those with <1cm disease (HR 1.36 CI 1.10-1.68)43 suggesting that optimal cytoreduction 
should still be regarded as a favourable outcome. 
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In clinical practice, a combination of radiographic opinion of staging CT images, diagnostic 
laparoscopic findings, co-morbidities, patient’s wishes and surgical expertise are used to 
decide on surgical suitability.  Currently, there are no clinically useful biomarkers that predict 
morbidity from surgery or the likelihood of achieving complete or optimal cytoreduction. 
 
Capillary density impacts on the total resistance of the capillary bed and thus capillary 
pressure and capillary pressure is vital to tissue fluid homeostasis and trans capillary 
exchanges.237  The assessment of SCD at presentation and post operatively in relation to these 
clinical aspects may provide an insight into the microvascular status that may then help to 
predict those more at risk of post-operative complications. 
 
We have seen in the previous chapter that SCD falls in response to chemotherapy.  The 
implication for this in clinical practice is important to ascertain particularly as to whether this 
dynamic change is indicative of response to treatment. 
 
In this chapter I attempt to investigate whether SCD at baseline and during treatment can 
predict survival, recurrence and surgical outcome and morbidity. 
 
5.2 Aims 
• To investigate whether SCD at baseline predicts OS, PFS or surgical cytoreduction 
• To investigate whether the change SCD before and after 3 cycles of treatment can 






This was a prospective cohort study and patients with a diagnosis of high grade serous ovarian 
cancer were invited to participate over an 18-month period.  Skin capillary density was 
measured at diagnosis (baseline) and prior to surgery after the first 3 cycles of chemotherapy 
(baseline to visit 2).  The absolute difference in values between this visit point was calculated.  
Treatment groups were split into those who had chemotherapy only and those who had 
chemotherapy and bevacizumab. 
 
A CT scan was conducted after 3 cycles of treatment in time with visit 2.  This CT was reported 
according to RECIST criteria which is further described in the main methods section.  Those 
with a partial response to chemotherapy and suitable fitness underwent debulking surgery 




In order to determine the impact of change in skin capillary density, the difference was 
dichotomised into above and below the mean.  Wilcoxon test and Kruskal Wallis was used to 
compare means.  Logistic regression was used to determine the effect on surgical outcomes 
and complications.  
 
Dichotomised variables were tabulated as high and low values above the mean.  The 
associations between the calculated difference in values and PFS and OS were assessed with 
Kaplan Meier plots stratified by the dichotomised variables. Log rank test was used to 
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ascertain significance in survival data.  Where relevant, statistical significance was described 




All women had neoadjuvant treatment and a diagnosis of high-grade serous carcinoma.  50 
women were recruited to the study.  As I wanted to investigate the association between 
baseline values and surgical outcome and the difference between baseline and visit 2, only 
42 women are included in this analysis.  Those who had primary surgery were excluded (n = 
5) and those who died after the first cycle of chemotherapy were also excluded (n = 3).  As 
regards to treatment, 36 (79%) had neoadjuvant carboplatin and paclitaxel chemotherapy 
and the remaining 6 (21%) received Bevacizumab alongside the first two cycles of 
chemotherapy.  6 of those who had neoadjuvant chemotherapy did not have surgery as they 












Table 5.1  Demographics of patients 
 N= 42 
Characteristic  
Age (years) at diagnosis 69.8 (11.2) 
<65 14 (33%) 
65-70 6 (14%) 
>70 22 (53%) 
BMI (kg/m2) 25.6 (4.74) 
History of hypertension* (yes) 4 (9.5%) 
Ca-125 2273 (69, 40000) 
Performance status at diagnosis  
0 6 (14%) 
1 30 (72%) 
2 6 (14%) 
Tumour stage  
3b 5(12%) 
3c 22 (52%) 
4 15 (36%) 
Treatment  
Neoadjuvant chemotherapy 33 (79%) 
Icon8b 6 (21%) 
Type of surgery   
Complete/optimal 28 (67%) 
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Suboptimal 8 (19%) 
Unfit/died/inoperable 6 (14%) 
Chemotherapy response score  
1 11 (26%) 
2 18 (48%) 
3 7 (17%) 
Bevacizumab treatment (Yes) 15 (36%) 
Death (Yes) 20 (48%) 
Recurrence (Yes) 34 (81%) 
 
5.4.1. Skin capillary changes prior to surgery 
 
Mean basal and maximal skin capillary density reduced between baseline and visit 2 but the 
drop was greater in those who received Bevacizumab (p=0.0023, p= 0.0125) (Table 5.2, figure 










Table 5.2.  The difference in skin capillary density (vessels/mm2) between baseline and visit 2 
according to treatment 
 Mean basal SCD 
(vessels/mm2) 




 Mean difference 
(SD) 
P value Mean difference 
(SD) 
P value 
Neoadjuvant chemotherapy (36) -3.89 0.0023 -4.36 0.0125 
ICON8b (6) -16.33 -14.17 
 











5.4.2 Skin capillary density at baseline and prediction of outcomes 
 
There was no significant difference in mean basal or maximal skin capillary density at baseline 
between the 3 groups of response reported at mid treatment CT although the p value 








Table 5.3 Skin capillary density (vessels/mm2) and CT response 
 
 Mean basal SCD 
(vessels/mm2) 
P value Maximal SCD 
(vessels/mm2) 
P value 
 Mean (SD)   Mean (SD)   
Complete response 73.2 (2.9) 0.07 77.0 (3.6) 0.06 
Partial response 63.4 (10.1) 68.6 (9.7) 
Stable disease 71.5 (0.7) 77.0 (0) 
 
 
5.4.2.1. Surgical resection outcomes 
 
Mean basal and maximal skin capillary density was higher at baseline in patients who had 
optimal surgery (p= 0.001, 0.0009 respectively) (Table 5.4). 
 
Table 5.4  Mean basal and maximal SCD (vessels/mm2) at baseline according to surgical 
outcome 
 Mean basal SCD 
(vessels/mm2) 
P value Maximal SCD 
(vessels/mm2) 
P value 
 Mean (SD)   Mean (SD)   
Optimal  6.9 (9.0)  0.001 71.67 (8.94)   0.0009 




All women who had Bevacizumab treatment prior to surgery had complete resection.  When 
I excluded those women (n=6) the significance remained the same as demonstrated in table 
5.5. 
 
Table 5.5  Mean basal and maximal SCD (vessels/mm2) at baseline according to surgical 
outcome (excluding ICON 8b patients) 
 Mean basal SCD 
(vessels/mm2) 
P value Maximal SCD 
(vessels/mm2) 
P value 
 Mean (SD)   Mean (SD)   
Optimal  66.5 (9.5)  0.002 71.2 (9.2)   0.001 
Suboptimal  55.4 (7.1)   61.13 (4.16)   
 
 
I used logistic regression to explore the association between surgical outcome and baseline 
skin capillary density which demonstrated for every increase in mean basal SCD by 1, there 
was a 19% chance of achieving complete or optimal resection (p= 0.014) (Table 5.6).  Similarly, 
for every increase in maximal SCD by 1, there was a 22% increase in chance of optimal or 







Table 5.6  Logistic regression of mean basal and maximal SCD (vessels/mm2) at baseline and 
surgical outcome 
 
Odd ratio (95% CI) P-value 
 
Maximal SCD at Baseline 
(vessels/mm2) 
0.78 (0.58, 0.98) 0.008 
 
Mean SCD at Baseline 
(vessels/mm2) 
0.81 (0.64, 0.98 0.014 
 
 
In order to explore the relationship with other factors, I also used logistic regression to 
explore the association between surgical outcome and the difference from baseline to Visit 2 
calculated for each of the angiogenic factors and skin capillary measurement (Table 5.7).  
 
Table 5.7.  Logistic regression of change in angiogenic factors and skin capillary density 
(vessels/mm2) from baseline to visit 2. 
Clinical factors Odd ratio (95% CI) P-value 
VEGF1 1.048 (0.947, 1.24) 0.241 
ANG11 1.00 (0.996, 1.004) 0.912 
SOLEND 0.85 (0.566,1.274) 0.430 
Mean Basal SCD (vessels/mm2) 0.91 (0.815, 1.018) 0.099 
Maximal SCD (vessels/mm2) 1.085(0.984, 1.195) 0.101 




For every 100-unit increase in VEGF after baseline, the odds of having optimal surgery is 




I used logistic regression to ascertain any association between SCD at baseline and post-
operative adverse events (Table 5.8).  There were no significant associations seen. 









Extended hospital stay 
(Yes/ No) 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
Max SCD 0.97 (0.90, 1.06) 0.530 1.12 (0.99, 1.28) 0.081 0.996 (0.90, 1.10) 0.935 
Mean SCD 0.97 (0.90, 1.05) 0.481 1.12 (0.98, 1.28) 0.474 0.998 (0.91, 1.10) 0.974 
 
5.4.3 Prediction of overall and progression free survival 
 
Patients with a smaller reduction in change in mean basal skin capillary density (those above 
the mean) had a shorter OS and PFS (mean 22.0 vs 22.5 and 16.5 vs 21.1 months) (figure 5.3, 
5.4).  This was also true of maximal skin capillary density (21.8 vs 23.1 and 15.8 vs 22.3 




Figure 5.3.  Overall survival according to change in mean basal skin capillary density 
(vessels/mm2) 








There was a significant difference in PFS according to the change in maximal skin capillary 
density with those who had a smaller reduction in SCD (change above the mean) having a 
shortened PFS (15.8 vs 22.3 months p= 0.010) (Figure 5.6). 
 

















5.4.4 Estimation of optimal skin capillary density 
 
5.4.4.1 Surgical outcomes 
 
I have shown that those who had optimal surgery had higher values of mean basal and 
maximal skin capillary density.  I performed a ROC analysis to define the optimal SCD that 







Table 5.9. Optimal values for SCD (vessels/mm2) and prediction of surgical debulking outcome 
SCD at Baseline 
(vessels/mm2) 
Optimal value Sensitivity Specificity AUC 
Maximal 66 78.8% 87.5% 0.833 
Mean basal 61 81.8% 87.5% 0.823 
 







AUC 0.823  
p=0.007 (CI 0.715-0.983) 
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5.4.4.2 Survival outcomes 
 
I carried out a ROC analysis for survival based on the same optimal cut off values for SCD but 






AUC 0.833  
p=0.006 (CI 0.738-0.981) 
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Table 5.10. Optimal values for mean basal and maximal skin capillary density (vessels/mm2) 
and prediction of overall survival 
Overall Survival     
SCD at Baseline Optimal value Sensitivity Specificity AUC 
Maximal 66 76.9 34.6% 0.530 
Mean basal 61 76.9% 34.6% 0.577 
Progression free survival 
SCD at Baseline Optimal value Sensitivity Specificity AUC 
Maximal 66 59.3% 16.7% 0.427 


















A reduction in skin capillary density was seen in all patients overall.  However, there was a 
significant difference in progression free survival in patients who had a smaller reduction 
(above mean) in maximal density of capillaries.  There was a trend to reduced overall survival 
also.  This trend was also demonstrated for both progression free and overall survival and 
mean basal skin capillary density although in these cases it was not significant.   
 
In regard to radiological tumour response, there was no difference in SCD at baseline and mid 
treatment CT response.  It was not possible to assess associations between SCD in relation to 
radiological response to Bevacizumab in my cohort as all patients who had Bevacizumab pre 
surgery had complete surgical resection and a complete response at mid treatment CT.   
 
However, there was a significant association between baseline SCD and surgical resection 
outcome with a higher maximal and mean basal SCD predicting increased likelihood of 
complete resection.  Maximal SCD of over 66 and mean basal over 61 at baseline predicts the 
probability of achieving optimal surgery in more than 80% of patients.  I was unable to 
demonstrate that SCD predicts risk of post-operative morbidity.   
 
Although it was not significant, there was a trend of higher baseline VEGF and increased 
likelihood of optimal debulking.  This further adds weight to the association of higher SCD and 
surgical outcome in that those patients with higher angiogenic activity as measured by SCD 
were more likely to achieve optimal surgical debulking. 
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There are no studies investigating capillary density and surgical treatments in cancer.  
Furthermore, there are none regarding SCD and response to chemotherapy.  It is difficult to 
place my work in the context of scanty literature, however I have established the potential of 
SCD to be a marker of chemotherapy response and prediction of surgical outcomes.   
 
The lack of demonstrable association between SCD and survival may be explained by the small 
numbers in the cohort and that data is not fully mature.  However, the association between 
change in SCD and PFS is a promising finding that suggests the role of SCD as a biomarker of 
response requires further investigation.  High micro vessel count within the tumour has been 
demonstrated to be associated with survival outcomes171, 172 and correlation between the 
tumour and peripheral vascular networks requires evaluation to ascertain whether SCD has a 




Skin capillary density at baseline is associated with surgical debulking outcome.  Various 
models exist to predict optimal debulking, but none are widely accepted in clinical practice 
and radiological assessment of disease is heavily relied upon.    Furthermore, a greater fall in 
structural skin capillary density during treatment is associated with reduced risk of 










Angiogenesis is key for tumour growth and recurrence.66  The tumour microvascular 
environment in ovarian cancer is characterised by disordered blood vasculature comprising 
of immature and dysfunctional vessels.69   
 
CD 31 is a glycoprotein that is expressed in endothelial cells and is a measure of microvessel 
density in solid tumours185 and therefore provides an assessment of tumour angiogenesis.  In 
a subgroup analysis of the phase III GOG-0218 trial, women with a high CD 31 at diagnosis 
had improved PFS and OS (19.9 vs 9.8 months HR = 0.40 95% CI 0.29-0.54 p= 0.0025 and 45.6 
vs 35.9 months HR = 0.68 95% CI 0.52-0.89 p=0.0155).188   OS and PFS were not improved by 
such a margin in the general non stratified cohort.  This is contradictory to many studies which 
demonstrate poorer OS and PFS in patients with high microvessel density.  Further work is 
needed to validate the potential predictive value of CD31 to target angiogenic treatment.    
PDGFR is a marker of pericytes which may be indicative of neo vascularised tissue and active 
angiogenesis.  High levels of expression have been linked to shorter OS and high grade 
tumours.193-195  
 
Alongside angiogenesis, uncontrolled cell proliferation is a hallmark of cancer growth.  Ki67 is 
a marker of cell proliferation and high-grade serous carcinoma of the ovary is associated with 
a high (>40%) and diffuse pattern of staining for Ki67.197  Low Ki67 has been shown to be 
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associated with poorer OS in a cohort of ovarian cancer patients, postulated to be secondary 
to reduced response of these tumours to chemotherapy.198 
 
Chemotherapy response score (CRS) is the most reproducible criteria for assessing in vivo 
tumour response to chemotherapy and prognostic significance of CRS has been 
demonstrated in small cohorts264 but has not be related to vascular markers or associated 
with surgical outcomes. 
 
I have established that skin capillary density is associated with optimal surgical debulking but 
there are no studies investigating tumour vasculature and proliferative markers to predict 
surgical outcomes.  Furthermore, there is no assessment of microvessel density pre and post 
chemotherapy and its relationship with chemotherapy response scores, nor have there been 
studies comparing vascular markers in the tumour milieu to the peripheral microvascular 
environment.   
 
6.2  Aims 
 
• To investigate whether tumour proliferation and vascular markers at baseline or at 
surgery can predict OS, PFS  
• To investigate whether tumour proliferation markers at baseline or at surgery can 
predict surgical cytoreduction, post-operative complications and response to 
chemotherapy (radiological CT response and histological chemotherapy response 
score) 
 132 
• To investigate the longitudinal changes in tumour proliferation and vascular markers 
after chemotherapy 
• To investigate the association between tumour vascular markers and skin capillary 
density 
 
6.3  Methods 
 
As previously outlined, this was a prospective cohort study and patients with a diagnosis of 
high grade serous ovarian cancer were invited to participate over an 18 month period.  Biopsy 
of metastatic tissue (omentum or peritoneum) was taken prior to treatment.  Patients who 
were suitable had debulking surgery either prior to chemotherapy or after 3 cycles of 
treatment where disease was too extensive.  The details of how tissue was prepared and 
analysed are described in detail in the main methods section (section 2.9 page 66).  CD 31, 
PDGFR and Ki67 were calculated by myself and a Pathologist in tissue taken at biopsy and at 
debulking surgery.  Chemotherapy response score was calculated by an expert Pathologist 
according to the International Collaboration on Cancer Reporting guidance as detailed in the 




Surgery included total abdominal hysterectomy, bilateral salpingo-oophorectomy, 
appendicectomy, omentectomy, and excision of peritoneal disease.  Extended procedures 
were those that included bowel resection, splenectomy, diaphragm resection and excision of 
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lymph nodes.  Surgery was scored 0-3: 0 for standard surgery, 1 for 1 additional extended 
procedure, 2 for 2 additional extended procedure and 3 for 3 additional extended procedures.   
 
Post-operative complications were defined as a complication that occurred within 30 days of 
surgery.  This included infection (wound, chest, urinary tract) and sepsis, renal failure, 
cardiopulmonary failure, blood transfusion, return to theatre, ileus, prolonged admission for 
more than 8 days, visceral injury, venous thromboembolism, ITU admission and death.   
 
All those women who had neoadjuvant treatment had computed tomography (CT) scans after 
3 cycles of treatment. These were discussed in the multi-disciplinary team (MDT)  in order to 
determine suitability for debulking surgery.  CT scans were reported according to RECIST 
criteria as partial response (PR), complete response (CR), stable disease (SD) or progressive 
disease (PD).  Further details of the RECIST criteria are described in the main methods section. 





When investigating the change in markers, the difference between baseline and visit two was 
calculated.  Women were assigned into 2 groups, those who had 3 cycles of chemotherapy 
and those who had 3 cycles chemotherapy plus Bevacizumab (ICON 8b). 
Dichotomised variables were tabulated as high and low values above the mean.  The 
associations between tumour markers and PFS and OS were assessed with Kaplan Meier plots 
stratified by the dichotomised biomarkers and with cox proportional hazards models using 
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univariate and multivariate models.  The degree of association was characterised by hazard 
ratios and confidence intervals. Logistic and linear regression was used to test association 
between variables and models were adjusted for treatment, age and stage.  Fishers exact test 
was used to assess the association between CRS and surgical outcome.  Kendalls tau-b 
correlation was used to measure the strength of association between CT response and 
tumour markers.  In order to test the difference between markers in groups Mann Whitney 
test was used.  Where relevant, statistical significance was described when p = <0.05.   
 
6.4  Results 
 
6.4.1. Tumour vasculature and proliferation markers at diagnosis 
6.4.1.1. Recruitment 
 
50 women were recruited into the study.  5 (10%) women had primary debulking surgery and 
were excluded from this analysis.  Descriptive data is included in the table 6.1 below. 
 
Table 6.1  Demographics 
 N= 45 
Characteristic  
Age (years) at diagnosis 69.9 (10.9) 
Ca-125 2218 (73, 40000) 
Performance status at diagnosis  
0 6 (13%) 
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1 31 (69%) 
2 8 (18%) 
Tumour stage  
3b 7(15%) 
3c 21 (47%) 
4 17 (38%) 
Treatment  
Neoadjuvant chemotherapy 39 (87%) 
Icon8b 6 (13%) 
Biopsy (pre surgery) 31 (69%) 
Type of surgery   
Complete/optimal 28 (62%) 
Suboptimal 8 (18%) 
Unfit/died/inoperable 9 (20%) 
Chemotherapy response score  
1 11 (24%) 
2 18 (40%) 
3 7 (16%) 
Bevacizumab treatment (Yes, pre surgery) 6 (13%) 
Death (Yes) 22 (49%) 
Recurrence (Yes) 35 (78%) 
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31 (69%) women who had neoadjuvant treatment had a biopsy taken to ascertain diagnosis.  
The remaining women had the diagnosis based on cytology and radiological imaging.  Of those 
who had a biopsy, tissue was taken from the peritoneum or omentum in all cases.   Table 6.2 
describes the mean levels of markers in the tissue for those taken at biopsy prior to 
treatment. 
 
Table 6. 2. Mean (SD) of tumour markers collected at biopsy  
 
 Ki67 PDGFR CD31 
Biopsy (n= 31) 49.2 (24.6) 4.3 (2.6) 5.3 (2.4) 
*Ki67 is recorded as a percentage figure.  PDGFR and CD31 is recorded as number of vessels 
counted 
 
6.4.1.2.Survival outcomes  
 
Ki 67 
19 (61%) biopsy samples recorded a high Ki67 (above mean 49.2%).  There was no association 








Figure 6.1.  Overall survival according to high and low Ki67 at biopsy 
 








20 (65%) biopsy samples recorded a high CD 31 count above the mean (5.3 vessels).  There 
was no association between high and low CD31 count and OS (23.2 vs 20.5 months) and PFS 
(21.2 and 15.2 months) 
 


















11 (35%) biopsy samples recorded a high PDGFR count above the mean (4.3 vessels)   
There was no association between high and low PDGFR count and OS (20.0 vs 22.4 months) 










Figure 6.5.  Overall survival according to high and low PDGFR at biopsy 
 






When values of CD31, Ki67 and PDGFR measured in biopsy samples were expressed 
continuously there was no association with risk of death or recurrence as detailed in table 6.3 
and 6.4. 
 
Table 6.3  Univariate analysis of tumour markers at biopsy and overall survival 
Tumour markers Hazard ratio (CI) P value 
Ki 67 0.989 (0.97-1.01) 0.307 
CD 31 1.043 (0.85-1.28) 0.688 
PDGFR 1.112 (0.94-1.31) 0.208 
*Ki67 is recorded as a percentage figure.  PDGFR and CD31 is recorded as number of vessels 
counted 
 
Table 6.4 Univariate analysis of tumour markers at biopsy and progression free survival 
Tumour markers Hazard ratio (CI) P value 
Ki 67 1.01 (0.99-1.02) 0.561 
CD 31 0.92 (0.73-1.15) 0.447 
PDGFR 0.98 (0.82-1.17) 0.832 
*Ki67 is recorded as a percentage figure.  PDGFR and CD31 is recorded as number of vessels 
counted 
 
There was also no evidence of association between proliferative markers and markers of 




6.4.1.3. Mid treatment CT response 
 
42 women had a mid-treatment CT.  3 women died after the first cycle of chemotherapy.  4 
(9%) women had a complete response at mid treatment CT.  2 (5%) had stable disease and 
the remaining 36 (86%) had a partial response.  Examining those 31 women who had a biopsy, 
tumour markers were dichotomised to assess an association with CT response.  There was a 
strong positive relationship between Ki67 and CT response (τb = .563, p = 0.003). 
 
10% (2/12) women with a low Ki67 had stable disease whereas none had a complete 
response.  Conversely 18% (3/17) with a high Ki67 had complete response to adjuvant 
treatment whereas no women with low Ki67 had a complete response to treatment.  
Categorised CD 31 did not have any correlation with tumour response as measured by CT 
imaging (Table 6.5). 
 
There was a significant association between complete response on CT scan and complete 










Table 6.5. CT response and levels of tumour markers 
 Ki67  CD31  PDGFR  












Complete response 0 3 1 2 2 1 
Partial response 10 14 9 15 16 8 








*2 women who had biopsy died before they had a CT 
 
6.4.1.4. Surgical resection 
When I compared baseline tumour markers with surgical resection outcomes, there was no 
significant difference in tumour makers between those who had suboptimal or optimal 
surgery (Table 6.6) 
 
Table 6.6 Comparison of tumour markers in those who had optimal and suboptimal surgery 
 Optimal Suboptimal P value 
Tumour markers    
Ki 67 22.3 (16.1) 26.4 (29.3) 0.77 
CD 31 4.1 (2.4) 3.1 (2.5) 0.43 
PDGFR 2.7 (2.0) 2.1 (2.4) 0.40 








41 (82%) women underwent elective debulking surgery.  9 (18%) women never had surgery 
as they were too unfit or died.  Of the 41 women who had debulking surgery, 33 (80%) cases 
had tissue available from surgery for analysis.  3 women had an open and close procedure 
where the disease was felt not to be resectable by the surgeon and no tissue was taken for 
histology in these cases.  Those 5 (10%) women who had primary surgery were also excluded 
as I wanted to compare a more homogenous group of patients and this group had no 
treatment prior to surgical resection.   
 
In order to assess the change in markers 21 women had tissue available from both biopsy and 
debulking surgery.  The remaining 10 who had a biopsy did not have tissue available from 
surgery for the following reasons (3 died after one cycle of chemotherapy, 3 had open close 









6.4.2.2  Surgical outcomes 
 
18 (44%) women had a post-operative complication.  Table 6.6 describes details of the post-
operative complications.  1 woman had 4 complications (wound urine, chest infection, ileus).  
1 had a late complication of deep vein thrombosis and cerebral vascular event at 35 days post 
operatively.  3 (7%) women had chemotherapy delayed due to post-operative complications 
(1 due to thrombosis, 2 due to prolonged recovery from surgery).  7 (17%) women had a 
prolonged hospital stay and 7 (17%) required intensive care admission.   
 
Table 6.7.  Description of complications at debulking surgery 
Complication (n=18) N (%) 
Haemorrhage 7 (17) 
Intestinal perforation 2 (5) 
Ileus 3 (7) 










10 (24%) women had extended procedures.  3 women had 2 extended procedure.  Table 6.8 





Table 6.8.  Details of extended procedures 
Extended procedure N (%) 
Splenectomy 3 (7) 
Para aortic LN resection 1 (2) 
Bowel resection/stoma 6 (15) 
Diaphragm resection 3 (7) 
 
 
2 (5%) women died in the post-operative period.  Both were within 30 days and post mortem 
examination detailed cause of death as pneumonia.  1 woman who died had a score of 1 as 
required a bowel resection. 
 
There was no difference in overall survival according to the surgical procedure score as 















I used logistic regression to ascertain association between markers at biopsy and 
complications at surgery.  For every increase in PDGFR by 1 there was a reduction in risk of 
post-operative complications (p=0.037) but no significance was found.  This model was 















Extended hospital stay 
(Yes/ No) 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
CD31  1.13 (0.75, 1.71) 0.560 0.83 (0.51, 1.36) 0.456 1.03 (0.68, 1.58) 0.886 
Ki67  1.01 (0.96, 1.06) 0.739 1.03 (0.97, 1.10) 0.361 1.03 (0.97, 1.08) 0.330 
PDGFR  0.42 (0.19, 0.95) 0.037 1.23 (0.66, 2.27) 0.510 0.67 (0.35, 1.29) 0.227 
*Ki67 is recorded as a percentage figure.  PDGFR and CD31 is recorded as number of vessels 
counted 
 
6.4.3 Longitudinal change in tumour proliferative and vascular markers after treatment 
 
Table 6.10 describes the mean and SD of tumour markers at biopsy and debulking surgery.  
There was a significant reduction of 20.7 % in Ki67 after treatment with chemotherapy and 
bevacizumab.  PDGFR was significantly reduced by 1.6.    CD 31 also decreased but the change 










Table 6.10 Tumour markers at biopsy and surgery.   







Ki 67 47.4 (22.2) 26.7 (18.4) -20.7 (25.7) 0.0008 
CD 31 4.8 (2.1) 3.9 (2.5) -0.8 (3.2) 0.19 
PDGFR 4.0 (2.8) 2.4 (1.9) -1.6 (3.1) 0.04 
*Ki67 is recorded as a percentage figure.  PDGFR and CD31 is recorded as number of vessels 
counted 
 
When looking at the changes in those who had chemotherapy only compared with those who 
had chemotherapy and bevacizumab (ICON 8b), there was a greater fall in CD 31 count in 
those women who had Bevacizumab with chemotherapy (p= 0.009).  The fall in PDGFR and 
Ki67 was not significantly different between the groups (Table 6.11). 
 
Table 6.11  Comparison of the difference in mean tumour markers according to treatment 







Ki 67 -18.3 (25.1) -26.7 (28.6) 0.50 
CD 31 0.27 (2.8) -3.5 (2.4) 0.009 
PDGFR -1.1 (3.2) -2.8 (2.6) 0.47 




I explored the association between surgical outcome and the difference from baseline to visit 
2 for the tumour markers (Table 6.12).  There were no significant associations found.  
However, a rise in ki67 decreased the odd of having an optimal resection by 9% and this 
approached significance. 
 
Table 6.12.  Logistic regression for debulking surgery outcome in relation to change in tumour 
factors after treatment 
Tumour markers OR (95% CI) P value 
Ki 67 0.91 (0.82-1.01) 0.057 
CD 31 1.1 (0.78-1.6) 0.56 
PDGFR 0.84 (0.58-1.2) 0.34 





I also used logistic regression to investigate whether the change in baseline to visit 2 was able 
to predict the odds of progression free survival or overall survival (Table 6.13).  Although a 
reduction in Ki67 was associated with worse OS was close to significance, no other 







Table 6.13.  Logistic regression for odds of OS and PFS in relation to change in tumour 
 OS  PFS  
Tumour markers OR (95% CI) P value OR (95% CI) P value 
Ki 67 1.1 (1.01-1.14) 0.057 0.97 (0.93-1.01) 0.071 
CD 31 1.3 (0.81-2.04) 0.29 1.27 (0.88-1.84) 0.21 
PDGFR 0.77 (0.54-1.01) 0.14 0.84 (0.61-1.17) 0.30 
*Ki67 is recorded as a percentage figure.  PDGFR and CD31 is recorded as number of vessels 
counted 
 
6.4.3.2. Correlation between change in markers 
 
I used a linear regression model to explore whether there was association between 
proliferative makers and the vasculature in the tumour (Table 6.14).  There is evidence of 
significant association between percentage change in CD31 and Ki67 with or without 
adjusting for treatment.  For every unit change (i.e. 1%) in Ki67 the percentage change of 









Table 6.14 Estimates of the association of %change in Ki67 with PDGFR/CD31.  
*Model estimates after adjusting for treatment.  
 
6.4.4 Chemotherapy response score 
 
Chemotherapy response score was recorded in 36 patients.  Poor was defined as 
chemotherapy response score as 1 and a good score 2 and 3 combined.  25 (69%) patients 
had a good score and 11 (31%) a poor score.  Figures 6.8 and 6.9 display CRS and OS and PFS.  
Overall and progression free survival was worse in women who had a poor chemotherapy 







 Estimate (SD) p-value 
Outcome:  %change in PDGFR  
%change in Ki67 0.004 (0.214) 0.986 
-0.070 (0.228)* 0.7646* 
Outcome:  %change in CD31  
 
%change in Ki67 
0.682 (0.137) <0.001 
0.652 (0.138)* <0.001* 
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Figure 6.8  Progression free survival according to good or poor chemotherapy response score 
(CRS) 
 
Figure 6.9  Overall survival according to good or poor chemotherapy response score (CRS) 
 
p = 0.002 
p =0.07 
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There was a significant association with CRS and surgical outcome.  Those patients with a 
‘good’ CRS were associated with having a complete or optimal debulking outcome at interval 
surgery (p=0.04).  
 
The change in tumour vasculature markers from baseline to surgery did not predict 
chemotherapy response score although a rise in Ki 67 was associated with reduced odds of a 
good score (p=0.045) (Table 6.15) 
 
Table 6.15.  Logistic regression for good or poor CRS in relation to change in tumour factors 
after treatment 
Tumour markers OR (95% CI) P value 
Ki 67 0.955 (0.913-.99) 0.045 
CD 31 0.8 (0.5-1.6) 0.24 
PDGFR 1.2 (0.9-1.7) 0.29 
 
6.4.5.Testing the association of SCD at baseline with CD31 at biopsy  
 
In order to ascertain whether there was a link between vascular marker in the tumour (CD31) 
and peripheral vasculature (SCD) I used linear regression (Table 6.16).  CD31 measured at 
biopsy was the main outcome.  For 1-unit increase in either maximal basal or mean capillary 
density, CD31 is expected to decrease by 0.06 and 0.07 respectively however this was not 
significant. 
I also tested the association between Ki67 and PDGFR to skin capillary density and no 
correlation was found.   
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Table 6.16. Estimates of the association between CD31 and SCD density. 
Variable Estimate (SD) p-value 
Maximal SCD at Baseline -0.068 (0.036) 0.157 
Mean basal SCD at Baseline -0.078 (0.046) 0.129 
 
I also investigated the association between the % change in tumour marker with the 
angiogenic markers and skin capillary density measurements recorded at baseline after 
adjusting for treatment and age. Increasing the value of VEGF by 100 units at baseline was 
associated with a fall in CD31 from biopsy to surgery (p= 0.0343) (Table 6.17). 
 
Table 6.17. Estimates of the association of %change in PDGFR and CD31 with each angiogenic 
marker and SCD measure. 
 Estimate (SD) p-value 
Outcome: % change in PDGFR   
VEGF at baseline  0.02226 (0.02357) 0.3653 
Max SCD at baseline -0.01623 (0.01975) 0.4274 
Mean basal SCD at baseline -0.01757 (0.01978) 0.3920 
   
Outcome: % change in CD31   
VEGF at baseline  -0.04925 (0.02039) 0.0343 
Max SCD at baseline 0.01062 (0.02042) 0.6123 






In this cohort there was a trend of worse OS in those women with low Ki67 at biopsy although 
this did not reach significance.  There was no difference in OS or PFS according to CD31 levels.   
There was a positive correlation between high Ki67 and CT response after 3 cycles of 
treatment.  This does correlate with aforementioned evidence in the literature that high Ki67 
levels at biopsy are associated with improved response to chemotherapy.197, 198  Response to 
chemotherapy radiologically is key to informing the MDT decision making regarding plans to 
proceed with surgery.  Histological assessment of response to chemotherapy as calculated by 
the CRS is based on the presence of viable tumour alongside regression associated 
inflammatory changes.255  A rise in Ki67 after treatment was associated with reduced 
likelihood of a good CRS.  Although this was close to significance it does go further to 
strengthen the association between cell proliferation and chemotherapy efficacy. 
 
The data does also validate the prognostic significance of CRS in regard to OS and PFS.  I was 
able to demonstrate a strong correlation of a good CRS and complete surgical resection which 
may be an explanation for the former association as complete surgical resection is accepted 
to be a significant factor in improved OS and PFS. 
 
This is the first study to investigate the longitudinal changes in tumour vasculature and 
proliferative markers after chemotherapy in ovarian cancer.  I have demonstrated a 
significant reduction in Ki67 and PDGFR after 3 cycles of chemotherapy.  CD31 did reduce by 
a greater amount in those who had Bevacizumab alongside chemotherapy compared to those 
who had chemotherapy alone.  I was not able to demonstrate an impact on OS, PFS in relation 
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to the degree of these changes.  This may be due to the lack of mature data and small numbers 
within this cohort who had matched tissue from both biopsy and debulking surgery.  
Nonetheless it is a promising finding that requires validation.   
 
I was unable to demonstrate any association between CD 31 or PDGFR and skin capillary 
density.  Previously I have demonstrated a significant association between skin capillary 
density and surgical resection.  This was not demonstrable in relation to tumour vasculature.   
 
6.6 Conclusion 
This is the first study to demonstrate a fall in Ki67 and PDGFR after chemotherapy for ovarian 
cancer.  High levels of Ki67 at diagnosis correlate to radiological tumour response and 














Chapter 7. The effect of anti-angiogenic therapy on skin capillary density 
 
7.1  Introduction 
 
Bevacizumab is a recombinant humanised monoclonal IgG antibody that targets VEGF and an 
anti-angiogenic therapy used in women with ovarian cancer.  Bevacizumab has been shown 
to improve progression free survival in women with ovarian cancer and those with a higher 
risk of disease progression have the greatest benefit.152, 153  Locally Bevacizumab is currently 
given as part of a trial or in first line treatment for women with stage 4 disease but despite 
extensive research there is no established biomarker for Bevacizumab that helps to target or 
monitor treatment.   
 
There are known side effects as a result of the use of Bevacizumab, the most common being 
hypertension.  Not only can this place women at increased risk of morbidity but can delay 
treatment causing clinical and psychological distress.  The mechanism of hypertension 
secondary to anti angiogenic treatment is multifactorial and endothelial dysfunction, 
thrombosis and capillary regression are all likely to play a role.153   
 
An association between blood pressure and skin capillary density has been investigated in 
healthy patients and a common feature in essential hypertension is that of microvascular 
rarefaction characterised by reduced capillary density.242-244  A small study of patients with 
renal cell cancer has linked a reduction in skin capillary density with treatment induced 
hypertension229 thus it is a reasonable hypothesise that SCD may be an independent clinical 





• To assess the change in SCD in a specific population of patients on anti-angiogenic 
therapy 
• To assess the effect of anti-angiogenic therapy on blood pressure and association with 
skin capillary density 




Women who received Bevacizumab alongside standard treatment for high grade serous 
ovarian cancer were included in this subgroup.  Pre -treatment measurements were those at 
baseline prior to treatment.  End of treatment measurements were after standard treatment 
was completed including surgery.  All the patients included in this cohort underwent interval 
debulking surgery.  At each visit skin capillary density was measured and blood pressure 
recorded.  Further details of skin capillary measurement are described in the main methods 
section (section 2.7 page 57).  Hypertension as defined as systolic blood pressure >140mmHg 
and diastolic blood pressure >90mmHg.  Non responders were defined as those who had a 








When investigating the change skin capillary density and blood pressure, the difference 
between baseline and end of treatment was calculated.  Wilcoxon test was used to compare 
blood pressure and SCD before and after treatment.  Dichotomised variables were tabulated 
as high and low values above the mean.  The associations between the baseline and calculated 
difference in values and PFS and OS were assessed with Kaplan Meier plots stratified by the 
dichotomised variables. Log rank test was used to ascertain significance in survival data.  
Linear regression was used to test association between blood pressure and skin capillary 






15 (30%)  women had Bevacizumab treatment.  6 (40%) of these had Bevacizumab treatment 
alongside chemotherapy from the start of treatment as part of the ICON 8b trial.  The 
remaining 9 (60%) women had Bevacizumab added after surgery.  This was due to stage 4 
disease or suboptimal debulking surgical outcome.  There were three occasions when 
treatment was delayed due to uncontrolled hypertension.   





Table 7.1  Demographics of patients 
 N= 15  
Characteristic  
Age (years) at diagnosis 66.5 (9.2) 
<65 5(27%) 
65-70 5 (27%) 
>70 10 (66%) 
BMI (kg/m2) 27.1 (4.56) 
History of hypertension (yes) 0 (0%) 
Ca-125 4298 (73, 40000) 
Performance status at diagnosis  
0 2 (13%) 
1 13 (87%) 
2 0(0%) 
Tumour stage  
3c 5 (34%) 
4 10(66%) 
Treatment  
Neoadjuvant chemotherapy 9 (60%) 
Icon8b 6 (40%) 
Type of surgery   
Complete/optimal 11 (73%) 
Suboptimal 4(27%) 
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Chemotherapy response score  
1 7 (47%) 
2 6 (40%) 
3 2 (13%) 
Death (Yes) 6 (40%) 
Recurrence (Yes) 12 (80%) 
 
7.4.2. Longitudinal change in skin capillary density during treatment 
 
Table 7.2 demonstrates the mean skin capillary density in patients before and after 
treatment.  The mean basal skin capillary density reduced by 12.8 (SD5.9) capillaries and the 
maximal by 13.6 (SD 4.8) capillaries. 
 
Table 7.2:  Mean (SD) of skin capillary density (vessels/mm2) before and after treatment with 
Bevacizumab. 
 Mean basal SCD 
Mean (SD) 
P value Maximal (SCD) 
Mean (SD) 
P value 
 Pre Post  Pre Post  
Skin capillary density 64.0 (9.1) 51.2 (10.9) 0.0019 68.0 (9.7) 54.4 (10.2) 0.0013 
 
Figures 7.1 and 7.2 demonstrate the individual plots of SCD at start and end of treatment and 
indicate a uniform reduction amongst all patients.  
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Figure 7.1:  Individual plots of maximal SCD (vessels/mm2) pre and post treatment with 
Bevacizumab 
 





































Capillary rarefaction in both mean basal and maximal SCD occurred after treatment with 
bevacizumab (p= 0.0019 and p= 0.0013 respectively).  Figures 7.3 and 7.4 demonstrate this 
change. 
 
Figure 7.3:  Box plot demonstrating fall in mean basal SCD (vessels/mm2) in patients after 










Figure 7.4:  Box plot demonstrating fall in maximal SCD (vessels/mm2) in patients after 




I then investigated whether the drop in skin capillary density was different according to the 
patients who responded compared to those who did not.  Non responders were classified as 
those who had a recurrence of their disease or progression on the end of treatment CT scan 
according to RECIST. 
 
Figures 7.5 and 7.6 demonstrate the fall in SCD stratified according to response to treatment.  





Figure 7.5:  Box plot demonstrating fall in mean basal SCD (vessels/mm2)  in patients after 
treatment with Bevacizumab according to response to treatment. 
  
Figure 7.6:  Box plot demonstrating fall in maximal SCD  (vessels/mm2) in patients after 





7.4.3 Blood pressure changes and skin capillary rarefaction  
 
There was also a rise in the diastolic and systolic blood pressure after treatment with 
Bevacizumab. I used a linear regression model to investigate the association between the 
change in mean basal and maximal skin capillary density to the change in blood pressure.  I 
demonstrated a linear inverse trend between fall in skin capillary density and rise in systolic 
and diastolic blood pressure (Figure 7.7). 
 
Figure 7.7: A.  Difference maximal SCD compared to systolic blood pressure. B. Difference 
mean basal SCD compared to diastolic blood pressure.  C.  Difference mean SCD compared to 
systolic blood pressure.  D.  Difference maximal SCD compared to diastolic blood pressure.  
All SCD measurements were in vessels/mm2. 
 
Figure 7.7 A.   
 
R2 0.552 P = 0.002 
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Figure 7.7 B 
 
 
Figure 7.7 C 
 
R2 0.454 P = 0.006 
 




Figure 7.7 D 
 
 
7.4.4 Survival outcomes 
 
In these patients treated with Bevacizumab I carried out survival analyses to see whether the 
vascular changes were related to clinical outcomes. 
 
The changes in maximal and mean basal skin capillary density did not have a significant 
predictive value for PFS (21 vs 19 months p= 0.568 and 22 vs 20 months p=0.657).  (Figures 
7.8A, B).  Those patients with a change in both mean basal and maximal skin capillary density 
above the mean hence a smaller reduction in the number of capillaries showed a trend to 
worse OS but this was not significant (24 vs 32 months p= 0.761 and 24 vs 31 months p=0.594) 




Figure 7.8: A.  Progression free survival according to values above and below the mean of the 
difference in mean basal SCD. B. Progression free survival according to values above and 
below the mean of the difference in maximal SCD.  C. Overall survival according to values 
above and below the mean of the difference in mean basal SCD.  D.  Overall survival according 
to values above and below the mean of the difference in maximal SCD.  All SCD measurements 
were in vessels/mm2. 
 








Figure 7.8 B 
 





Figure 7.8 D 
 
 
I also looked at mean basal and maximal SCD at baseline in this subgroup of women who 
received Bevacizumab treatment.  Those women with higher SCD at baseline showed a trend 
to worse OS but this was not significant (27 vs 29 months p=0.200) (Figure 7.9 A, B).  In both 
these analyses when the means were dichotomised the same results were seen hence both 








Figure 7.9: A.  Overall survival according to values above and below the mean in baseline 
mean basal and maximal SCD.   B. Progression survival according to values above and below 
the mean in baseline mean basal and maximal SCD.  All SCD measurements were in 
vessels/mm2. 
 





























In this chapter I have investigated a small subgroup of the study population to assess the 
effect of Bevacizumab on SCD and ascertain whether these changes are related to clinical 
outcomes.  I have been able to demonstrate capillary rarefaction with Bevacizumab 
treatment and a direct association with the development of hypertension.  I found no 
difference in the capillary rarefaction according to response to Bevacizumab treatment.  
There was a trend for improved overall survival in those patients who had a greater drop in 
SCD but this was not significant.   
 
In this subgroup, both functional and structural rarefaction occurred which corresponds with 
a reduction in the number of capillaries as well as non-perfusion of the capillary networks.  
This effect on skin capillary density may be explained by VEGF inhibition.  Reduced endothelial 
cell survival secondary to dysfunction, thrombosis and apoptosis with subsequent destruction 
of micro vessels have been postulated as mechanisms.265, 266  Additionally, capillary non 
perfusion may be due to reduced vasodilation due to impaired nitric oxide synthesis as a 
result of VEGF blockade.251  These processes are likely to cause increased vascular tone and 
impaired vasodilation which could lead to hypertension.252, 265 
 
A common feature in essential hypertension is that of microvascular rarefaction characterised 
by reduced capillary density.242  Similar to that described in this data, this structural decline 
in capillary density is seen in the skin and contributes to increased systemic vascular 
resistance and hypertension.242-244  I did not demonstrate a significant association with blood 
pressure and capillary rarefaction in those treated with cytotoxic therapy alone which may 
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suggest that the development of hypertension may also be a result of capillary rarefaction in 
these patients.   
 
Hypertension is a recognised side effect of Bevacizumab treatment and the prevalence of 
grade 2-3 hypertension has been reported to be as high as 22%.153, 249  In some cancer sites 
such as breast and colorectal cancer, hypertension may represent a biomarker of tumour 
response to anti angiogenic therapy265 and has been shown to be linked to improved overall 
survival.232, 233 
 
I have not been able to demonstrate SCD rarefaction in Bevacizumab treatment with 
improved OS or PFS.  However, the association between reduction in SCD and rise in blood 
pressure means we may be able to predict and manage hypertension in a timely fashion by 




Both functional and structural capillary rarefaction occurred in patients with Bevacizumab 
treatment and this appears to be of a greater magnitude than that seen in patients on 
cytotoxic chemotherapy alone.  There is a strong association with capillary rarefaction and 
hypertension in patients treated with Bevacizumab, the mechanism of which is likely to be 
multifactorial.  Although there is no significant association of capillary rarefaction in these 




Chapter 8:  General discussion 
 
I conducted a longitudinal cohort study to investigate skin capillary density in ovarian cancer.  
In this study I recruited 50 women with high grade serous ovarian cancer and studied them 
at 5 time points starting at diagnosis.  I studied the longitudinal effects of cancer treatment 
on skin capillary density and correlations with serum and tumour angiogenic factors.  I have 
explored the association of skin capillary with cancer outcomes and surgical resection and 
morbidity in ovarian cancer patients.   
 
I made a number of novel findings and in this chapter, I aim to reflect on the main findings 
and discuss them in the context of the current literature and my original hypotheses.  I will 
consider the limitations of my study and the future implications and further study in skin 
capillary density in ovarian cancer which is a novel and promising area of research. 
 
8.1 Summary of main findings and implications in research 
 
8.1.1 Capillary rarefaction occurred during treatment for ovarian cancer and VEGF level 
reduced during treatment 
 
Capillary rarefaction occurred in all women irrespective of treatment group.  The largest drop 
in SCD was between baseline and visit 2, after 3 cycles of chemotherapy with or without 
Bevacizumab.  VEGF and Ang1 also demonstrated a reduction during treatment. 
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The overall trend of decrease in VEGF seen in my study is supported by other studies in other 
cancer sites in the literature where serum VEGF fell after resection of tumours and completion 
of chemotherapy.214, 261, 262  VEGF levels did rise transiently after surgery in the immediate 
post-operative period.  This may be reflection of increased angiogenesis for healing and 
hypoxia mediated stimulation of VEGF.259 
 
Ang 1 also fell in patients during treatment.  Raised Ang 1 levels are found in ovarian cancer 
patients compared to controls.97, 139  Pre-treatment high Ang 1 have been shown to be 
associated with improved PFS for patients treated with Bevacizumab.217, 267  Additional 
attempts to assess molecular biomarkers for response to tyrosine kinase inhibitor Sunitinib, 
decreasing levels of Ang 1 were associated with improved PFS.140  Although I was not able to 
demonstrate an increased magnitude of fall in levels in patients on Bevacizumab this is the 
first study to demonstrate the dynamic change of levels during treatment which may be a 
result of reduced tumour bulk and angiogenesis. 
 
A new addition to the literature from this study is the parallel fall in skin capillary density that 
occurred alongside a reduction in VEGF. 
 
Skin capillary density is a measure of microvascular networks and the dynamic change in my 
cohort is a promising finding that can provide an indication of angiogenic activity.  Vascular 
endothelial growth factor (VEGF) is a potent inducer of angiogenesis and directly induces 
endothelial cell proliferation.66  It is logical therefore that a fall in VEGF and Ang 1 corresponds 
with a fall in SCD as they act synergistically to stimulate angiogenesis and Ang 1 along with 
VEGF have been shown to increase capillary density in animal studies.268  
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It is likely that there may also be a direct impact of cytotoxic chemotherapy on angiogenesis 
and skin capillary density as well as the effect of the cancer itself.  This is supported by my 
finding that capillary rarefaction occurred during treatment with chemotherapy only. 
 
To my knowledge, capillary rarefaction in patients on cytotoxic chemotherapy has not been 
demonstrated before in the literature.  The capillary rarefaction in all patients was both 
structural and functional.   
 
Taxanes target microtubules disrupting mitosis and normal cell division leading to 
apoptosis.269  Vascular dysfunction from cytotoxic drugs is multifactorial and chemotherapy 
agents as well as the cancer itself are likely to have an impact.  Decreased endothelial nitric 
oxide bioavailability after cytotoxic treatment causes reduced vasodilation and perfusion.  
Oxidative stress and pro inflammatory cytokines can lead to platelet activation, thrombosis 
and capillary regression.263  This may suggest that capillary density is impacted directly by 
taxane chemotherapy. 
 
8.1.2  Capillary rarefaction occurred during anti angiogenic treatment and was correlated 
with a rise in blood pressure 
 
Those women who had bevacizumab had a greater fall in skin capillary density from start to 
end of treatment compared to those on chemotherapy alone.  Both functional and structural 
rarefaction occurred which corresponds with a reduction in the number of capillaries as well 
as non-perfusion of the capillary networks.   
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This effect on skin capillary density can be explained by reduction in VEGF due to reduced 
tumour activity as alluded to above.  However further reduction in VEGF by the direct 
inhibition of Bevacizumab may have additive effect on capillary rarefaction. 
 
The effects on capillaries secondary to anti angiogenic treatments may be secondary to the 
neutralisation of VGEF effects on the vessel wall and endothelial cells.  Reduced endothelial 
cell survival secondary to dysfunction, thrombosis and apoptosis with subsequent destruction 
of micro vessels have been hypothesised as mechanisms of reduction in skin capillary density 
secondary to VEGF blockade.265, 266  Additionally, capillary non perfusion may be due to 
reduced vasodilation due to impaired nitric oxide synthesis.252, 270   
 
These processes are likely to cause increased vascular tone and impaired vasodilation which 
may explain to correlation between Bevacizumab and hypertension.252, 265 
 
There is supporting evidence of reduction in SCD due to VEGF blockade which has also been 
demonstrated in patients who received sunitinib for metastatic renal cell cancer.229, 234  
Hypertension was correlated with this, and regrowth of the microcapillary network occurred 
after treatment was discontinued.234  It is likely given this evidence that capillary rarefaction 
does play a role in VEGF inhibitor-induced hypertension.  However, it may not be the sole 
factor. 
 
The mechanism for Bevacizumab induced hypertension is debated.  Veronese et al. refuted 
the theory it was related to adrenergic or renovascular cause and found no difference in 
humoral factors during treatment with anti-angiogenic therapy despite a rise in blood 
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pressure being commonplace.270  Mourad et al. reported a decrease in endothelium 
dependant vasodilation due to impaired nitric oxide synthesis as a result of VEGF blockade in 
Bevacizumab therapy251 which resulted in a reduction in functional and structural capillary 
density. 
 
A common feature in essential hypertension is that of microvascular rarefaction characterised 
by reduced capillary density.242  A structural decline in capillary density is seen in skin beds in 
patients with essential hypertension which contributes to increased systemic vascular 
resistance.  This rarefaction appears to precede the development of hypertension.243, 244  
 
Vascular rarefaction as a consequence of VEGF inhibition is likely to be multifactorial.   
Angiogenic factors such as VEGF stimulate the growth of new capillaries which is expected to 
reduce vascular resistance.251  In mouse models vessel narrowing and cessation of blood flow 
was an initial response to anti VGEF treatment followed by regression mediated by 
endothelial cell apoptosis.257  
 
The concurrent rise in blood pressure and capillary rarefaction seen in patients on 
Bevacizumab has not been demonstrated in ovarian cancer before.  This association was not 
seen in those who had a capillary rarefaction during cytotoxic treatment alone.  This 
interesting paradox may hint that capillary rarefaction in those patients on anti-angiogenic 
therapy is a result of hypertension rather than the cause.  However, the magnitude of 
rarefaction in those on Bevacizumab was considerably greater which may be the explanation 
for hypertension in this group alone if it is indeed mediated by increased vascular resistance. 
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Platinum based chemotherapy such as cisplatin is associated with hypertension and 
endothelial cell dysfunction, platelet activation and reduced NO availability are mechanisms 
that are implicated in the aetiology.263  Paclitaxel halts endothelial cell proliferation by 
reducing smooth muscle migration.271, 272  When Taxanes are combined with angiogenic 
inhibitors at other cancer sites (breast and lung) the hypertensive effects seem to be 
heightened.238, 273 
 
8.1.3 Skin capillary density at baseline is strongly associated with outcome of debulking 
surgery 
 
I have found a significant association between skin capillary density at baseline and surgical 
debulking outcome.  For every unit increase in mean basal and maximal SCD the chance of 
optimal debulking increased by 19 and 22% respectively.  Maximal SCD of over 66 
vessels/mm2 and mean basal over 61 vessels/mm2 at baseline predicted the probability of 
achieving optimal surgery in more than 80% of patients.  Although in my cohort 78% of those 
who underwent debulking surgery had optimal resection, reports in the literature are variable 
ranging between 50-80%.  The higher number reported are in studies of ultra-radical surgery 
where morbidity is higher.253, 274-278 
 
Various models have been constructed to aid accurate prediction for surgical resection using 
a combination of imaging techniques, clinical features such as albumin and presence of 
ascites, laparoscopy, and biological markers.279  However, no reliable and reproducible 
method has yet been established.  Radiological assessment is heavily relied upon to aid 
decision making and many patients have suboptimal outcomes.  It is clear that suboptimal 
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surgery does not improve survival but increases morbidity therefore appropriate patient 
selection for surgery is paramount. 
 
I hypothesise that high skin capillary density at baseline may result in increased tissue 
perfusion and thus increase delivery and efficacy of chemotherapy and bevacizumab 
treatment.  This is turn is likely to have a favourable outcome of reducing tumour bulk thus 
increasing the likelihood of complete resection at surgery.   
 
Skin capillary density in isolation or in combination with other factors may predict the success 
of surgical resection.  I have demonstrated that skin capillary density can predict surgical 
resection with high sensitivity and specificity.  This would not only guide appropriate 
counselling for patients, but may prevent excess morbidity by avoiding suboptimal outcomes.   
 
8.1.4.  Skin capillary density at baseline does not significantly predict progression free or 
overall survival 
 
I found no association between baseline SCD and cancer survival outcomes.  As regards 
change in capillary density before and after treatment, those patients who had a greater 
reduction in maximal (structural) capillary density had an improved progression free survival.  
There was a trend to reduced overall survival but this was not significant.  For those patients 




We have discussed earlier that hypertension may represent a clinical biomarker of tumour 
response231 and studies in patients with renal cell carcinoma that have demonstrated a link 
between treatment induced hypertension and improved PFS after treatment with 
antiangiogenic inhibitors including Bevacizumab and Sunitinib.226-230  If capillary rarefaction 
precedes hypertension then it is logical that a greater reduction in SCD may predict improved 
outcomes.   
 
Demonstration of a significant association between SCD and recurrence gives promise of SCD 
as a biomarker in ovarian cancer treatment.  The relationship between structural capillary 
rarefaction and reduced recurrence is likely to be multifactorial as previously discussed.  
However, if this is a reflection of reduced angiogenesis as a result of effective treatment, it 
opens the possibility that SCD may be an easily measured surrogate of this. 
 
8.1.5.  Skin capillary density is higher in patients with cancer compared to healthy controls 
 
Although there is variation in values of skin capillary density in the normal population, I have 
demonstrated a clear increase in both maximal and mean basal SCD in those with ovarian 
cancer compared to healthy controls.   
 
Currently a combination of factors such as CA 125, radiological and clinical assessment are 
used to determine the presence of ovarian cancer.31, 32  There is no reliable screening tool for 
ovarian cancer33 and the biological indolent nature means most cases present with advanced 
disease.  Serum VEGF levels are increased in those with malignant compared to benign 
ovarian tumours95-97  secondary to increased angiogenesis and tumour derived VEGF.  We 
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have previously discussed the association between VEGF and SCD which may also explain the 
finding in this group.  
 
8.1.6.  Capillary rarefaction does not correlate with tumour vasculature and proliferative 
markers.  Proliferative marker Ki67 is associated with chemotherapy response 
 
This is the first study to investigate the longitudinal changes in tumour vasculature and 
proliferative markers after chemotherapy in ovarian cancer.  I have found a reduction if Ki67 
and PDGFR after treatment with chemotherapy.  High Ki67 at diagnosis was associated with 
an improved radiological response to chemotherapy and there was a trend of rise in Ki67 after 
treatment and reduced likelihood of a good CRS.   
 
This does correlate with evidence in the literature that high Ki67 levels at biopsy are 
associated with improved response to chemotherapy.198  Histological assessment of response 
to chemotherapy as calculated by the chemotherapy response score (CRS) is based on the 
presence of viable tumour alongside regression associated inflammatory changes.  A rise in 
Ki67 after treatment was associated with reduced likelihood of a good CRS.  Although this was 
close to significance it does go further to strengthen the association between cell proliferation 
and chemotherapy efficacy. 
 
CD31 did reduce in those who had Bevacizumab alongside chemotherapy compared to those 
who had chemotherapy alone.  I was not able to demonstrate any impact on OS or PFS or any 
correlation with tumour vascular markers and SCD. 
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CD31 has been associated with worse OS in ovarian cancer patients185 however there is 
heterogeneity in methods for calculating microvessel density (MVD) which means results 
from multiple studies are difficult to correlate.  MVD in cancer models has been shown to 
decrease after anti angiogenic therapy due to apoptosis of tumour endothelial cells69 and 
CD31 did fall more significantly in the subgroup treated with Bevacizumab in this study 
compared to those treated with chemotherapy alone. 
 
PDGFR also fell during treatment.  PDGFR is a marker of pericytes which are required for 
stabilisation of new vessels and are a maker of active angiogenesis.192, 193  The dynamic change 
in PDGR may be more representative of the impact of treatment on angiogenic activity in the 
tumour. 
 
I was not able to demonstrate a correlation between SCD and CD31 or PDGFR.  CD31 reflects 
the microvascular environment in the tumour whereas SCD is more representative of the 
wider capillary network under influence of other factors.  In comparison to the values of CD31 
in other studies, my values are low.  This may be because of the method used to measure 
CD31.  Nevertheless, I have demonstrated that SCD is dynamic and changes over short time 
periods.  Inconsistencies with the values of MVD in studies may be that it is not a measure of 
active tumour angiogenesis. 
 
8.1.7.  Skin capillary density as a surrogate marker of angiogenesis 
 
It can thus be argued quite confidently that SCD is a marker of active angiogenesis.  
Bevacizumab works by inhibiting VEGF and thus reducing angiogenesis.  As we have seen SCD 
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falls as a result of bevacizumab’s effect on microvessels.251  Skin capillary density as a marker 
of angiogenesis is further supported by the concept of capillary rarefaction with age when 
angiogenesis is reduced.280  As discussed cytotoxic chemotherapy causes vascular dysfunction 
which leads to hypoperfusion and capillary regression263 and I have demonstrated capillary 
rarefaction in patients undergoing this treatment also.  Capillaroscopy allows access to 
capillary function and angiogenesis and may allow clinicians to monitor the effects of cancer 
treatment by assessing vascular reactivity.   
 
8.2 Strengths and limitations  
 
8.2.1.  Skin capillary density technique and confounding factors 
 
I made attempts to validate my values by measuring SCD in a group of age matched controls 
and those with benign disease.  I also developed a learning curve to improve my skill in 
obtaining a good image.  Initial images were not as good quality as I was learning the 
technique, so I ensured I practised on colleagues before recruiting patients.   
 
Additionally, I allowed time for each visit with patients to ensure the environment and 
conditions were suitable for reliable and reproducible measurements.  There is however a 
degree of intra observer and interobserver variability, but the above measures were taken to 
reduce this as much as possible.  I recorded videos to allow time to count capillaries and did 
this after each visit.  I did have access to an automated counter but found this was not reliable. 
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A limitation is this method of skin capillary estimation is the difficulty in highly pigmented 
skin.  Melanin absorbs light strongly in the visible spectrum which makes assessing SCD in this 
population difficult.  This has limitations for applicability to the general population and 
recruitment of patients to studies.  Fluorescence video microscopy could be an alternative 
method for these patients.   
 
I was unable to demonstrate that SCD was predictive of response to Bevacizumab or survival.  
This may be due to the small numbers and lack of power in the study.  Additionally, as the 
data matures this may be more apparent.  PFS and OS in my cohort was shorter than those 
reported in recent trials with the addition of Bevacizumab.35, 153  This may be because women 
had advanced stage 3c or 4 disease but may have had an impact on my findings. 
Nevertheless, this study has established the potential of recruiting patients alongside larger 
multicentre trials as capillaroscopy is non-invasive and inexpensive it is likely to be welcomed 
by patients. 
 
Ageing is a known factor in capillary rarefaction due to loss of dermal volume.281  The age 
range of this cohort was narrow and the majority of patients were over 65.  Age was a factor 
adjusted for in statistical modelling.  Additionally, capillary rarefaction is described in 
hypertension.  No patients in the cohort had uncontrolled hypertension.  Evidence suggest 






8.2.2.  Study cohort and sample size 
 
My cohort was of patients with advanced ovarian cancer with the majority having stage 3c 
and 4 disease.  These women have poorer outcome and pose a challenge to treatment thus 
were of most interest.  Additionally, the vast majority of patients with ovarian cancer present 
with advanced disease so it can be argued that my cohort is representative of clinical reality.   
 
A limiting factor was sample size.  This was influenced by the time constraints of the 
recruitment period due to the length of my research post and working alone to recruit 
patients and collect data.  Furthermore, the number of women diagnosed with ovarian cancer 
varied on a monthly basis.  The data collection (n=256 visits) was also time consuming as 
patient interactions lasted around 60 minutes at each visit.  Calculating SCD from videos 
required additional time.  Counting vessels in tissue also required around 15 minutes per slide 
by two people and ELISA experiments took several weeks to complete.  The only way to 
increase the sample size would have been to prolong my research period or engage additional 
staff from other sites to recruit and collect data.  The sample size may have contributed to 
the lack of associations drawn between changes in SCD and markers and outcomes.  
Additionally, allowing the data to mature over time and then further reanalysis may reveal 
more information. 
 
I was only able to recruit 6 women who were enrolled in the ICON8b trial which limited the 
amount of data available in women treated with Bevacizumab.  However, during the study 
period, a total of 7 women were enrolled into the trial by the department.  The remaining 
patient that was not included in my study was not approached for recruitment due to 
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significant emotional distress and I felt it unethical to consent. As the visits are carefully timed 
with treatment, I was unable to re discuss at a later date.   The low number in this subgroup 
is a reflection of the cancer centre recruitment and suitability of patients for the trial.  
 
I did not miss a visit for either blood collection or SCD measurement.  This required scrupulous 
organisation and flexibility to ensure there were no missing data points.  I was unable to 
follow women up after they stopped Bevacizumab as treatment was continued as 
maintenance for 15 months by which point I had completed my research time. 
 
8.2.3.  VEGF 165b and serum samples 
 
The inability to produce data for VEGF165b was disappointing.  Multiple attempts were made 
to improve the technique and despite this, accurate curves were only produced for some 
plates.  Even in those cases  the values were erratic or undetectable.  Nonetheless this is an 
interesting finding. Since I carried out the ELISAs for this research a recent study in breast 
cancer patients found similar results in that 34% of patients had unmeasurable levels of 
VEGF165b.  Levels did rise after treatment with chemotherapy, but levels were heterogenous 
with large interindividual variability.214   
 
VEGF165b has been found to be down regulated in cancer tissue in favour of the switch to 
the proangiogenic isoform which is vital for tumour development.214, 282, 283  To my knowledge 
there have only been two studies measuring VEGF165b in blood samples in cancer.208, 214  The 
second study found the ratio of VEGFxxxb to VEGF could be helpful in selecting patients for 
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Bevacizumab due to a correlation between PFS in those with low levels of anti-angiogenic 
isoform.208 
 
The fact that levels are undetectable is in keeping with down regulation of VEGF165b at tissue 
level and are consequently too so low to be detectable by this particular ELISA kit.   
 
Another reason that may explain the lack of measurable values is the use of serum.  The 
aforementioned study found levels were higher and more often detectable in plasma samples 
in healthy controls.  All my samples were serum as is much of the data in VEGF and cancer.  I 
recognise that levels may be elevated due to the effects of thrombocyte VEGF production.  
However much of my work has been investigating trends over treatment and the consistent 
use of serum as well as standardised preparation of samples means that data is still 
interpretable and meaningful. 
 
I stored serum in 500 micro litre aliquots.  On reflection the ELISAs required smaller volumes 
which meant time was spent aliquoting samples at a later date.  My limited funding and 
number of samples meant I was only able to measure a small number of cytokines.  Luminex 
micro array assays would have allowed a wider range of cytokines to be measured using 
smaller volumes of sample. 
 
8.3.  Future work and implications 
 
The potential for further research in this area is limitless but I will focus on suggestions that I 
would wish to pursue.  
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8.3.1.  Skin capillary density 
 
I have demonstrated in this proof of concept study that skin capillary density shows promise 
as a marker of angiogenesis in ovarian cancer and potential biomarker.  In order to develop a 
biomarker, it first has to demonstrate dynamic change in response to an intervention and I 
have been able to demonstrate this with SCD and cytotoxic treatment and anti-angiogenic 
therapy.   
 
Skin capillary density now needs to be studied on a wider scale and measured alongside 
interventions either in current trials or in a new study.  In the first instance accurate sample 
size calculation to inform a repeated larger scale longitudinal study to replicate my work.  The 
study could also be conducted as a cross sectional evaluation to provide greater numbers and 
require multi centre collaboration. 
 
A longitudinal study mapping skin capillary changes during maintenance treatment with 
Bevacizumab and after completion of treatment would provide additional information 
regarding capillary rarefaction and anti-angiogenic treatment. 
 
I did not find any difference in SCD between those with benign tumours and cancer but 
showed a significant difference between healthy controls and cancer.  An informative study 
would be one that measures SCD in benign disease on a larger scale as the number in my 
cohort were small. 
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The development of a validated automated capillary counter would improve reliability and 
efficiency for capillaroscopy.  This is important is capillaroscopy is to be considered on a wider 
scale as part of a large trial or integrated into clinical practice.   
 
8.3.2.  Angiogenic markers 
 
VEGF165b in cancer is a promising area for future research.  Collaboration is required among 
research groups to validate a reliable method and ELISA technique for detection in a larger 
cohort to determine whether VEGF165b has a role in stratifying patients for anti-angiogenic 
therapy. 
 
I was unable to demonstrate any change in soluble endoglin with treatment.  Soluble endoglin 
is implicated in vascular resistance and hypertension but I was not able to demonstrate any 
correlation with serum levels and capillary rarefaction.  More recently however endoglin has 
been thought to be more reliable in identifying vessels involved in tumour angiogenesis 
compared to CD31.258  Some studies have demonstrated an association between increased 
MVD assessed by CD105 and worse outcome, advanced stage and suboptimal primary 
cytoreductive surgery in ovarian cancer.175, 179, 180, 284  An additional area of research would be 
to measure endoglin in ovarian cancer tissue and correlate with SCD.  
Serum biomarkers of Bevacizumab are still allusive.  Proteomic analysis of paired serum 
samples from women in my study who received chemotherapy or chemotherapy and 
Bevacizumab would allow identification of potential pathways of further interest which may 
allude to potential new biomarkers of bevacizumab.  I have begun work on this and conducted 
proteomics on matched samples and am embarking on data analysis. 
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8.3.3.  Clinical applications 
 
I have seen that Bevacizumab treatment was withheld in some cases which caused a delay in 
treatment and undoubted angst for the patient.  The link between hypertension and capillary 
rarefaction is clear and I have demonstrated this in patients taking Bevacizumab.  It could be 
feasible that SCD is used as a biomarker of hypertension secondary to Bevacizumab and 
predict the onset of hypertension to allow timely instigation of treatment thus ensuring 
patients do not suffer both the physical and mental effects of hypertension and treatment 
delay.  Capillaroscopy could be easily incorporated into chemotherapy pre assessment clinics 















8.4  General conclusion 
 
Skin capillary density has not been measured in patients with ovarian cancer before.  Neither 
have serum or tissue markers been monitored during cytotoxic treatment.  I have 
demonstrated a dynamic change in SCD during treatment.  The concept of capillary 
rarefaction in the presence of anti-angiogenic therapies is plausible.  However, reduction in 
SCD with cytotoxic treatments such as chemotherapy is less explored and has not been 
demonstrated before.  Additionally, skin capillary density is able to predict surgical resection 
outcomes in women undergoing interval debulking surgery for advanced disease. 
 
Although this data requires validation in larger studies, it can be postulated that skin capillary 
density could be useful as a biomarker of response to treatment and cancer outcomes and 
act as a surrogate marker of angiogenesis in cancer. It is a reproducible, cheap and non-
invasive investigation that is acceptable to patients and shows promise in helping to guide 
treatment and prognostic information in the era of personalised medicine.   
 
I believe I have demonstrated proof of the need for ongoing work to enable skin capillary 
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Appendix 3.  Patient information sheets and Consent Forms 
OCCLUDES STUDY CONSENT FORM 
Ovarian Cancer and CapiLlary DEnsity of Skin: Role of skin capillary density in Epithelial 
Ovarian Cancer 
Please sign initials in box below: 
1. I confirm that I have read and understand the information sheet (version 
1.8) dated 19.12.2016 for the above study. I have had the opportunity to ask 
questions about the study and I understand why the research is being carried 
out. 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. If I withdraw consent, I understand that 
samples already taken will be kept as part of the study but no further tests 
will be taken. 
3. I agree to allow data to be retained in anonymised form for five years after 
the completion of this study in line with NHS regulations. 
4. I consent to the removal, storage and use of my tissue and blood samples 
for the above study in line with the Human Tissue Act 2004. 
5.  I agree that the samples collected during this study can be stored and used 
for future studies, with ethical approval 
6. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by responsible individuals from regulatory 
authorities or from the NHS Trust where it is relevant to my taking part in 
research.  I give permission for these individuals to have access to my 
records. 
7. I give permission to be contacted either by phone, email or by post for 
research purposes 
8. I consent to my GP being informed of my participation in this study 
9. I agree to take part in the above study 
     
Name of Patient (Capitals)  Date  Signature 
     
Researcher           Date                  Signature 
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OCCLUDES STUDY INFORMATION SHEET 
Ovarian Cancer and CapiLlary DEnsity of Skin  
Role of skin capillary density in Epithelial Ovarian Cancer 
Invitation: 
You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with friends, relatives and your GP 
to decide whether you would like to take part.  Ask us if there is anything that is not clear or 
if you would like more information.   Thank you for reading this. 
What is the Purpose of this Study: 
Currently ovarian cancer is treated by a mixture of surgery and chemotherapy. The 
chemotherapy drugs given are the same for all patients. We do not have a way of working 
out who will benefit from chemotherapy or surgery first, or who may need a different type of 
chemotherapy. This study may help us to work this out by using some simple new tests.  
Why have I been Chosen? 
You have been chosen as we you have been diagnosed with ovarian cancer. Please let the 
doctor know if you suffer from any blood circulation problems, as you might not be suitable 
for the study. 
Do I have to take part? 
Taking part in this research is entirely voluntary. It is up to you whether or not to take part. If 
you do decide to take part you will be asked to sign a consent form. You are free to change 
your mind and withdraw from the study at any time. If you do withdraw you do not have to 
give your reasons for doing so and it will not affect the standard of care you receive. 
What will happen to me if I take part? 
You will be seen on 5 occasions at St. Michael’s Hospital when you are attending for routine 
visits. You will not have to make any extra visits.  
The first visit will be before you start treatment either with an operation or chemotherapy.  
At each visit you will be asked to sit in a chair whilst your forearm and hand will be placed on 
an armrest. A video will be recorded of the blood vessels on the skin using a microscope and 
a camera; a painless technique. You will be able to view your own blood vessels on the 
computer screen if you wish. A baby blood pressure cuff will be wrapped around the bottom 
 225 
of a finger and then inflated to increase the number of blood vessels that we can see. The 
video will continue recording for two minutes whilst the cuff is blown up.  
This test will be done after the operation, 9 weeks later and at the end of treatment. 
At each visit, a blood sample (about 2 tablespoons) will be taken at the same time as  your 
routine blood tests. This blood test will be used only for research , and would not provide 
information that can be used for your health care.   
If you have surgery, the tissue removed will be sent to the pathologist for routine testing.  
Once the routine lab tests are finished we will request a very small amount of the tissue (that 
would otherwise have been disposed of) for research. 
What do I have to do? 
You do not need to make any changes to your lifestyle except to abstain from coffee and 
smoking for at least 2 hours before you attend for your capillary study.  
What will happen to the samples? 
After analysis for the study with your consent tissue samples will be stored anonymously in a 
laboratory and kept for potential future studies with ethical approval. 
What are the possible Disadvantages and Risks of taking part? 
Capillary microscopy is a painless test. You may feel slight tingling in your finger when the 
blood pressure cuff is blown up and for the 2 minutes that it remains inflated, but this 
disappears as soon as the cuff is released. 
What are the possible Benefits of taking part? 
This study is of no direct benefit to you but it may help us understand how different ovarian 
cancers respond to more specialised chemotherapy. Your medical care would not be 
adversely affected by not taking part in this study.  
What if something goes wrong? 
We do not envisage any harm coming to you as a consequence of taking part. If you have any 
concerns or other questions about this study, or the way it has been carried out, you should 
contact the Patient Support & Complaints Team, Trust Headquarters, University Hospitals 
Bristol, Marlborough Street, Bristol, BS1 3NU. Tel No: 0117 342 3604 email: 
pals@uhbristol.nhs.uk 
Will my participation in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept 
strictly confidential.  
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What will happen to the results of the Research Study?  
It is anticipated that the results from this research study will be published in a medical journal 
several months after its completion. The exact journal is not known at this stage, although we 
will be able to give this information and the actual results at a later date. No participants of 
this research study will be identified in any report/publication. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people called a Research 
Ethics committee to protect your safety, rights, well-being and dignity. This study has been 
reviewed and given a favourable opinion by the NRES Committee. 
CONTACT FOR FURTHER INFORMATION: 
If you require further information regarding any part of this research study, please feel free 
to contact Dr Gemma Cass (Gynaeoncology Research Fellow) or Dr. Sarah Platt (Subspecialty 
Registrar) or Carol Shahin, Research coordinator on 0117 3425756 
Research team: 
Dr Gemma Cass, Gynaeoncology Reseach Fellow 
Dr Vivek Nama, Consultant Gynaecologist 
Dr Sarah Platt, Subspecialty Fellow, Gynae-Oncology 
Mr Amit Patel, Consultant Gynaecologist 
Dr Axel Walther, Consultant Oncologist 
Dr Jo Bailey, Consultant Gynaecologist 
Mr John Murdoch, Consultant Gynaecologist 
 
Many thanks for your interest in the study and taking the time to read this information. 









Appendix 4.  Table S4.1.  Variability in SCD measurements 
 
Intraobsever    Interobserver    
1 2 Ab diff SD % Ab diff 1 2 Ab diff SD % Ab diff 
56 56 0 0 0 45 50 5 4 11 
54 57 3 2 6 65 63 2 1 3 
66 68 2 1 3 65 60 5 4 8 
50 48 2 1 4 61 66 5 4 8 
53 55 2 1 4 62 63 1 1 2 
53 52 1 1 2 55 58 3 2 5 
69 71 2 1 3 68 70 2 1 3 
46 49 3 2 7 67 63 4 3 6 
80 82 2 1 3 49 48 1 1 2 
67 69 2 1 3 63 60 3 2 5 
54 53 1 1 2 59 60 1 1 2 
57 60 3 2 5 63 60 3 2 5 
54 55 1 1 2 55 56 1 1 2 
72 72 0 0 0 78 74 4 3 5 
70 75 5 4 7 82 79 3 2 4 
65 66 1 1 2 55 50 5 4 9 
78 80 2 1 3 59 57 2 1 3 
58 58 0 0 0 66 68 2 1 3 
75 71 4 3 5 55 60 5 4 9 
71 71 0 0 0 48 49 1 1 2 
    3     5 
    2.2     2.9 
 
  
 
 
